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ABSTRACT 
SULEIMAN, MUNA, M., Masters : June : 2019, PHARMACY 
Title: The Role of p90 Ribosomal S6 Kinase and Autophagy in Sunitinib and 
Ponatinib-Induced Cardiotoxicity 
Supervisor of Thesis: Fatima, Mraiche. 
In recent years, the paradigm cancer management has shifted towards a 
targeted approach. Among the newly targeted anticancer therapies are ponatinib and 
sunitinib, small molecules tyrosine kinase inhibitors (TKIs), used for various types of 
cancer. Despite their superb anticancer effects, their use has been associated with 
cardiovascular toxicities. Therefore, the present study aimed to investigate the 
cardiotoxic effects associated with ponatinib and sunitinib and to define the 
underlying cardiotoxic signaling pathways.  
In the current study, an in vitro rat cardiomyoblast (H9c2) model was used to 
assess the cardiotoxic effects of sunitinib and ponatinib following 6 and 24 hours. 
Cardiomyoblast loss was characterized by MTT assay and flow cytometer analyses. 
Cardiomyoblast hypertrophy was assessed by measuring H9c2 cell surface area and 
atrial natriuretic peptide (ANP) mRNA expression. The potential molecular 
mechanisms of cardiotoxicity was examined by measuring p90RSK phosphorylation 
and autophagic flux. Both ponatinib and sunitinib induced the highest cardiotoxic 
effects among the screened TKIs. Sunitinib and ponatinib treatment reduced H9c2 
cardiomyoblast cell viability and induced apoptotic cell death. Sunitinib treatment 
induced cardiomyoblast hypertrophy, while ponatinib treatment caused cellular 
detachment and cellular shrinkage. In terms of molecular pathways, ponatinib 
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treatment induced p90RSK phosphorylation and autophagy, while sunitinib treatment 
inhibited p90RSK activity and induced autophagy. Inhibition of p90RSK or 
autophagy using BID or CQ, respectively, was associated with further cellular death. 
Our study compared the cardiotoxicity of different clinically-approved TKIs 
and identified the potential mechanisms of cardiotoxicity. This study demonstrated for 
the first time the different cardiotoxic effects associated with ponatinib treatment in 
H9c2 cell line. 
  
v 
 
DEDICATION 
 
 
 
 
 
To my beloved mother 
  
  
vi 
 
ACKNOWLEDGMENTS 
I thank Almighty Allah as without His mercy, blessings, and guidance, I would never 
have completed this work. 
I would like to thank my supervisor and mentor Dr. Fatima Mraiche for everything 
she taught me throughout the MSc thesis journey and for helping me to become the 
junior scientist I am today. Thank you very much for your invaluable support, 
guidance, patience, care, and all the great advice you have given me. Words will 
never be enough to express how grateful I am for all the opportunities you provided 
me with!  
My appreciation goes to my co-supervisor Dr. Huseyin Yalcin for his continuous 
support and encouragement. I would also like to thank my Graduate Student 
Supervisory Committee members; Dr. Shahab Uddin, Dr. Hesham Korashy, Dr. 
Hazem Elewa, and Dr. Mohamed Izham for their support, insightful comments and 
guidance.  
I would like to acknowledge Dr. Fatima Mraiche’s lab members; Mr. Nabeel 
Abdulrahman and Ms. Jensa Joseph for their technical assistance, support, and 
continues encouragement. Also, I would like to thank Dr. Siveen kodappully from the 
interim translational research institute (iTRI) for training me and providing support 
during flow cytometer experiments. 
I thank Qatar University and the College of Pharmacy for funding me to disseminate 
this work at an international conference. 
Finally, I would like to extend my sincere gratitude to my loving family; my parents 
and my brothers, for their tremendous support and encouragement throughout my 
academic endeavors.  
  
vii 
 
  TABLE OF CONTENTS 
DEDICATION ............................................................................................................... v 
ACKNOWLEDGMENTS ............................................................................................ vi 
LIST OF TABLES ..................................................................................................... xiii 
LIST OF FIGURES .................................................................................................... xiv 
ABBREVIATIONS ................................................................................................... xvii 
CHAPTER 1: INTRODUCTION .................................................................................. 1 
1.1. Cardio-oncology: An Emerging Multi-Disciplinary Field ................................ 1 
1.2. Cardiotoxicity .................................................................................................... 2 
1.3. Chronic Myeloid Leukemia (CML): Epidemiology, Pathophysiology, and 
Management ................................................................................................................... 5 
1.3.1. Ponatinib ........................................................................................................ 7 
1.3.1.1. Ponatinib-Induced Cardiotoxicity .............................................................. 9 
1.4. Renal Cell Carcinoma (RCC): Epidemiology, Pathophysiology, and 
Management ................................................................................................................. 13 
1.4.1. Sunitinib ....................................................................................................... 14 
1.4.2. Sunitinib-Induced Cardiotoxicity................................................................. 16 
1.5. Speculated Molecular Mechanisms of Sunitinib and Ponatinib-Mediated 
Cardiotoxicity .............................................................................................................. 19 
1.5.1. Ribosomal S6 Kinase (RSK) ....................................................................... 19 
1.5.1.1. Role of RSK in Cellular Processes .......................................................... 20 
  
viii 
 
1.5.1.2. RSK and Cancer ....................................................................................... 21 
1.5.1.3. RSK and Cardiovascular Diseases ........................................................... 22 
1.5.1.4. RSK in TKIs-Induced Cardiotoxicity ...................................................... 23 
1.5.2. Autophagy .................................................................................................... 24 
1.5.2.1. Monitoring Autophagy............................................................................. 25 
1.5.2.2. Role of autophagy in Cellular Processes ................................................. 26 
1.5.2.3. Autophagy and Cancer ............................................................................. 26 
1.5.2.4. Autophagy and Cardiac Diseases............................................................. 27 
1.5.2.5. Autophagy in Small Molecule TKIs-Induced Cardiotoxicity .................. 29 
1.6. Thesis Rationale, Hypothesis and Objectives .................................................. 30 
1.6.1. Rationale ...................................................................................................... 30 
1.6.2. Hypothesis.................................................................................................... 31 
1.6.3. Objectives .................................................................................................... 31 
CHAPTER 2: MATERIALS AND METHODS ......................................................... 33 
2.1. Materials .......................................................................................................... 33 
2.2. Methods............................................................................................................ 35 
2.2.1. Culturing and Maintaining Embryonic BDIX Rat Myoblast Cell Line 
(H9c2) 35 
2.2.2. Drug Treatment ............................................................................................ 36 
2.2.3. Treatment Flow (Experimental flow and methods can be found in figures 
  
ix 
 
2.1 and 2.2) .................................................................................................................. 38 
2.2.4. Cell Viability Assay (MTT Assay) .............................................................. 42 
2.2.5. Cardiomyocyte Hypertrophy Marker ........................................................... 42 
2.2.5.1. Cardiomyocyte Hypertrophy Marker: Cell Surface Area ........................ 42 
2.2.5.2. Cardiac Hypertrophy Marker: ANP mRNA expression .......................... 43 
2.2.5.2.1. Reverse Transcription Polymerase Chain Reaction (RT-PCR) ............... 43 
2.2.6. Flow Cytometer Studies ............................................................................... 45 
2.2.7. Immunoblotting............................................................................................ 46 
2.2.8. Evaluation of Autophagic Flux .................................................................... 46 
2.3. Statistical Analysis ........................................................................................... 47 
CHAPTER 3: RESULTS ............................................................................................. 48 
3.1. Screening for Cardiotoxicity Induced by Various Tyrosine Kinase Inhibitors 48 
3.1.1. Cell Viability: MTT Assay .......................................................................... 48 
3.1.2. Cell Viability: Flow Cytometer ................................................................... 51 
3.1.3. Cell Death: Necrosis and Apoptosis ............................................................ 53 
3.1.4. Cell Morphology and Cardiac Hypertrophy Markers: Cell Surface Area ... 55 
3.1.5. Cell Morphology and Cardiomyocyte Hypertrophic Markers: Cell Size .... 58 
3.2. Studies on Sunitinib and Ponatinib .................................................................. 60 
3.2.1. Cardiomyocyte Hypertrophic Markers – Atrial Natriuretic Peptide (ANP) 
mRNA Expression ....................................................................................................... 60 
  
x 
 
3.2.2. Apoptosis – Caspase-3 Activation ............................................................... 61 
3.3. Molecular Mechanisms of Cardiotoxicity Induced by Sunitinib and Ponatinib .. 
 .......................................................................................................................... 63 
3.3.1. Role of p90 Ribosomal S6 Kinase (p90RSK) Activation in Sunitinib and 
Ponatinib-Induced Cardiotoxicity ................................................................................ 63 
3.3.2. Role of Autophagy in Sunitinib and Ponatinib-Induced Cardiotoxicity ...... 65 
3.4. Cardiotoxic Studies of Sunitinib and Ponatinib – Reduced Treatment Duration 
 .......................................................................................................................... 68 
3.4.1. Cell Viability ................................................................................................ 68 
3.4.2. Cell Death: Necrosis and Apoptosis ............................................................ 70 
3.4.3. Cell Morphology and Cardiomyocyte Hypertrophic Markers: Cell Size .... 72 
3.4.4. Cell Morphology and Cardiomyocyte Hypertrophic Markers: Atrial 
natriuretic peptide (ANP) mRNA Expression ............................................................. 73 
3.5. Molecular Mechanisms of Cardiotoxicity Induced by Sunitinib and Ponatinib 
– Role of p90 Ribosomal S6 Kinase (p90RSK) and Autophagy Inhibition ................ 75 
3.5.1. p90 Ribosomal S6 Kinase Activity .............................................................. 75 
3.5.1.1. Sunitinib-Mediated Regression of p90 Ribosomal S6 Kinase ................. 75 
3.5.1.2. Ponatinib-Mediated Induction of p90 Ribosomal S6 Kinase .................. 79 
3.5.2. Evaluation of Autophagic flux ..................................................................... 82 
3.5.2.1. Sunitinib-Mediated Induction of Autophagy ........................................... 82 
3.5.2.2. Ponatinib-Mediated Induction of Autophagy .......................................... 85 
  
xi 
 
3.5.3. Cell Viability ................................................................................................ 87 
3.5.4. Cell Death: Necrosis and Apoptosis ............................................................ 89 
3.5.5. Apoptosis – Caspase-3 Activation ............................................................... 93 
1.6.3.1. Sunitinib or Ponatinib-Mediated Caspase-3 Regression ......................... 93 
3.5.6. Cardiac Hypertrophy and Cell Morphology ................................................ 96 
3.5.6.1. Cell Surface Area and Cell Size............................................................... 96 
CHAPTER 4: DISCUSSION ....................................................................................... 98 
4.1. Ponatinib and Sunitinib-Induced Cardiomyoblast Loss and Hypertrophy ...... 99 
4.1.1. Cardiomyoblast Loss ................................................................................. 100 
Cell Viability .............................................................................................................. 100 
Mechanism of Cell Death .......................................................................................... 102 
4.1.2. Cardiomyoblast Hypertrophy, Cell Morphology, and Cell Size................ 103 
Sunitinib Versus Ponatinib-Induced Cardiotoxicity .................................................. 104 
4.2. Role of p90RSK and Autophagy in Ponatinib and Sunitinib-Induced 
Cardiomyoblast Loss and Hypertrophy ..................................................................... 105 
p90RSK ...................................................................................................................... 105 
Autophagy .................................................................................................................. 106 
4.3. Role of Inhibiting p90RSK and Autophagy in Ponatinib and Sunitinib-Induced 
Cardiomyoblast Loss and Hypertrophy ..................................................................... 108 
4.3.1. Cardiomyoblast Loss ................................................................................. 108 
  
xii 
 
Cell Viability .............................................................................................................. 108 
Mechanism of Cell Death .......................................................................................... 109 
4.3.2. Cardiomyoblast Hypertrophy, Cell Morphology, and Cell Size................ 110 
CHAPTER 5: CONCLUSION .................................................................................. 111 
5.1. LIMTATIONS ............................................................................................... 112 
5.2. FUTURE DIRECTIONS ............................................................................... 113 
REFERENCES .......................................................................................................... 114 
 
  
  
xiii 
 
LIST OF TABLES 
Table 2.1: List of the antibodies used to determine the protein expression ................. 34  
Table 2.2: Tyrosine kinase inhibitor dilution trials ...................................................... 38 
Table 2.3: Conditions of reverse transcription used to convert RNA into cDNA ....... 44 
Table 2.4: Conditions of semi-quantitative Reverse Transcription-PCR (qPCR) ....... 44 
Table 2.5: List of primes used for semi-quantitative Reverse Transcription-PCR 
(qPCR)  ........................................................................................................................ 45 
Table 3.1: Summary of Findings – Sunitinib or ponatinib-Induced Cardiotoxicity: 24 
hours ............................................................................................................................. 67 
Table 3.2: Summary of Findings – – Sunitinib or ponatinib-Induced Cardiotoxicity: 6 
hours ............................................................................................................................. 74 
  
  
xiv 
 
LIST OF FIGURES 
Figure 1.1: Chemical structure of ponatinib, free base  ................................................. 8  
Figure 1.2: Mechanism of action of ponatinib ............................................................... 8 
Figure 1.3: Summary of a proposed model of molecular mechanisms of ponatinib-
induced cardiotoxicity .................................................................................................. 12  
Figure 1.4: Chemical structure of sunitinib, free base ................................................. 15 
Figure 1.5: Mechanism of action of sunitinib .............................................................. 16 
Figure 1.6: Summary of a proposed model of molecular mechanisms of sunitinib-
induced cardiotoxicity .................................................................................................. 18 
Figure 1.7: Illustration of ribosomal S6 kinase (RSK) activation ............................... 21 
Figure 1.8: Hypothetical model of sunitinib and ponatinib-induced cardiotoxicity .... 32 
Figure 2.1: Experimental procedures used to determine tyrosine kinase inhibitors 
(TKIs)-induced cardiotoxicity ..................................................................................... 40 
Figure 2.2: A summary of the experimental flow of TKIs treatment and parameters 
analyzed ....................................................................................................................... 41 
Figure 3.1: The effect of various tyrosine kinase inhibitors on the cell viability of 
H9c2 cardiomyoblasts .................................................................................................. 49  
Figure 3.2: The effect of dimethyl sulfoxide (DMSO) on H9c2 cell viability ............ 50 
Figure 3.3: The effect of sunitinib or ponatinib treatment on H9c2 cardiomyoblast cell 
viability  ....................................................................................................................... 52 
 
  
xv 
 
Figure 3.4: Sunitinib or ponatinib induce H9c2 cardiomyoblasts apoptotic cell death ... 
  .............................................................................................................................. 54 
Figure 3.5: Sunitinib-induced H9c2 cardiomyoblast hypertrophy and ponatinib-
induced H9c2 cardiomyoblast shrinkage ..................................................................... 56 
Figure 3.6: Sunitinib-induced H9c2 cardiomyoblast hypertrophy and ponatinib-
induced cellular detachment and cardiomyoblast loss ................................................. 57 
Figure 3.7: Sunitinib and ponatinib treatment causes H9c2 cardiomyoblast shrinkage .. 
  .............................................................................................................................. 59  
Figure 3.8: Sunitinib treatment for 24 hours induces atrial natriuretic peptide (ANP) 
mRNA expression in H9c2 cardiomyoblast ................................................................ 60 
Figure 3.9: Sunitinib or ponatinib-induced apoptosis is not mediated through a 
caspase-3 pathway in H9c2 cardiomyoblasts .............................................................. 62  
Figure 3.10: Ponatinib induces p90 Ribosomal S6 kinase (p90RSK) phosphorylation 
in H9c2 cardiomyoblasts.............................................................................................. 64 
Figure 3.11: Ponatinib treatment activates cellular autophagy in H9c2 
cardiomyoblasts ........................................................................................................... 66 
Figure 3.12: Sunitinib and ponatinib treatment reduced H9c2 cardiomyoblast cell 
viability following 6-hours treatment .......................................................................... 69 
Figure 3.13: Sunitinib or ponatinib treatment for 6 hours regresses necrosis and 
induces apoptosis ......................................................................................................... 71  
Figure 3.14: Effect of 6 hours treatment with sunitinib or ponatinib on H9c2 
cardiomyoblast cell size ............................................................................................... 72 
  
xvi 
 
Figure 3.15: Ponatinib treatment for 6 hours induces atrial natriuretic peptide (ANP) 
mRNA expression ........................................................................................................ 73 
Figure 3.16: Sunitinib treatment for 6 hours reduces phosphorylation of p90RSK 
protein expression ........................................................................................................ 78 
Figure 3.17: Ponatinib treatment for 6 hours induces phosphorylation of p90RSK 
protein expression ........................................................................................................ 81 
Figure 3.18: The effect of 6-hours treatment sunitinib on autophagic flux ................. 84 
Figure 3.19: The effect of 6-hours treatment ponatinib on autophagic flux ................ 86 
Figure 3.20: Effect of RSK and autophagy inhibition on sunitinib and ponatinib on 
H9c2 cardiomyoblast cell viability .............................................................................. 88 
Figure 3.21: Effect of RSK and autophagy inhibition on necrotic cell death following 
ponatinib and sunitinib ................................................................................................. 91 
Figure 3.22: Effect of RSK and autophagy inhibition on apoptotic cell death following 
ponatinib and sunitinib ................................................................................................. 92 
Figure 3.23: The effect of RSK and autophagy inhibition on caspase-3 protein 
expression following sunitinib treatment ..................................................................... 94 
Figure 3.24: The effect of RSK and autophagy inhibition on caspase-3 protein 
expression following ponatinib treatment .................................................................... 95 
Figure 3.25: The effect of RSK and autophagy inhibition on ponatinib and sunitinib-
induced cardiomyoblast damage .................................................................................. 97 
 
 
  
xvii 
 
ABBREVIATIONS  
ABL, Abselon murine leukemia 
ALL, Acute lymphoblastic leukemia 
AMPK, AMP-activated protein kinase 
AT1R, ANG II type I receptor  
AT2R, ANG II type II receptor  
BAD, BCL-2-associated death promoter 
BAP-1, BRCA-associated protein-1 
BAX, BCL2-associated X protein 
BCR, breakpoint cluster region 
BID, BI-D1870  
BNIP3, Bcl-2/E1B-interacting protein 3 
BNP, brain natriuretic peptide 
ccRCC, Clear cell RCC  
CHF, Congestive heart failure 
chRCC, Chromophobe RCC  
CMA, Chaperone-mediated  
CML, Chronic myeloid leukemia 
CQ, Chloroquine  
CREB, cAMP response element-binding protein 
CTRCD, Cancer therapy-related cardiac dysfunction  
DAPK, death-associated protein kinase  
eNOS, Endothelial nitric oxide synthase 
ERK, Extracellular signal-regulated kinase 
  
xviii 
 
FDA, Food and Drug Administration 
FGFR, Fibroblast growth factor receptor 
FLT1/3, FMS-like tyrosine kinase-1 and 3 
GIST, Gastrointestinal stromal tumor 
GRB2, Growth factor receptor-bound protein 2  
GSK3, Glycogen synthase kinase 3 
HF, Heart failure 
HER2, Human epidermal growth factor receptor 2 
hiPSC-CMs, Human induced pluripotent stem cell–derived cardiomyocytes 
hiPSC-ECs, Human induced pluripotent stem cell–derived endothelial cells 
hiPSC-FCs, Human induced pluripotent stem cell–derived cardiac fibroblasts 
HIF, hypoxia-inducible factor 
IE, immediate-early 
IRIS, International Randomized study of Interferon-α and low-dose cytarabine versus 
STI571 
I/R, Ischemia/reperfusion 
Kd, Dissociation constant 
LAMP2, lysosome-associated membrane protein-2  
LC3, Microtubule-associated protein 1 light chain 3  
LV, Left ventricular 
LVEF, Left ventricular ejection fraction 
MAPK, Mitogen-activated protein kinase 
MEK1/2, MAPK-extracellular signal-regulated kinase 1/2 
mTOR, Mammalian target of rapamycin 
  
xix 
 
NCI, National Cancer Institute 
NFATc4, Nuclear factor of activated T-cells 4  
NF-kB, Nuclear factor-kB  
NHE1, Na+/H+ exchanger 1 
NO, Nitric oxide 
NRVMs, Neonatal rat ventricular cardiomyocytes  
PACE, Ponatinib Ph+ ALL and CML Evaluation 
PBRM-1, Polybromo-1 
PDGFR, Platelet-derived growth factor receptor 
PI3K, Phosphatidylinositol 3 kinase 
pRCC, Papillary RCC 
PTEN, Phosphatase and tensin homolog  
RCC, Renal cell carcinoma 
RET, Rearranged during transfection 
ROS, Reactive-oxygen species  
RSK, Ribosomal S6 kinase 
RTK, Receptor tyrosine kinase  
SDS-PAGE, Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
Ser/Thr, Serine-threonine  
SENP2, Small ubiquitin-like modifier-specific protease-2  
SETD-2, SET domain containing-2 
SOS, Son of sevenless 
SRF, Serum response factor 
STAT5, Signal transducer and activator of transcription-5 
  
xx 
 
TKIs, Tyrosine kinase inhibitors 
TSC2, Tuberous sclerosis complex 2 
US, United States 
VEGFR 1-3, Vascular endothelial growth factor receptor 1-3 
VHL, Von Hippel-Lindau  
 
  
  
1 
 
CHAPTER 1: INTRODUCTION 
1.1. Cardio-oncology: An Emerging Multi-Disciplinary Field  
Cancer and heart diseases remain the top leading cause of morbidity and 
mortality in developed society (1). Cancer survival rate and prognosis have 
improved substantially over the past 30 years due to advancement in early detection 
and treatment modalities (2). Despite the clinical success in cancer management, 
traditional and novel anticancer approaches have increased the prevalence of 
cardiovascular morbidities and mortalities among cancer patients and survivors (2-
4). To satisfy the need for specialized discipline to provide cardiovascular care for 
cancer patients and survivors, a new medical field, cardio-oncology or onco-
cardiology, was introduced (5, 6).  
Cardio-oncology is an emerging multi-disciplinary field that focuses on 
understanding the pathophysiology of cancer therapy-induced cardiotoxicity and 
providing early detection and treatment for cancer patients and survivors (7). 
Multiple societies, such as The Canadian Cardiovascular Society, have developed 
guidelines and position statements to help clinicians to better deal with the arising 
issue of cardiotoxicity (8, 9). The Canadian Cardiovascular Society guidelines 
addresses four main areas to guide the cardiovascular care in cancer patients. These 
areas include: i) the identification of the population at high risk to develop 
cardiotoxicity; ii) detection and prevention strategies of cardiotoxicity; iii) 
cardiotoxicity treatment; and iv) the establishment of a multi-disciplinary approach 
for the management of cancer therapy-induced cardiovascular toxicity (9).   
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1.2. Cardiotoxicity          
Although anticancer therapy-induced cardiotoxicity or cancer therapy-related 
cardiac dysfunction (CTRCD) is well-known, there is no agreed upon definition for 
cardiotoxicity (10, 11). Several cardiovascular and cancer organizations have 
defined cardiotoxicity according to clinical or subclinical manifestations (11, 12). 
The National Cancer Institute (NCI) describes cardiotoxicity as “toxicity that affects 
the heart” (13, 14). Whereas, the cardiac review and evaluation committee for 
trastuzumab (Human epidermal growth factor receptor 2; HER2 monoclonal 
antibody) clinical trials, defines cardiotoxicity as i) cardiac disease with a decreased 
left ventricular ejection fraction (LVEF); ii) symptoms of congestive heart failure 
(CHF); iii) signs of heart failure (HF); and iv) a symptomatic reduction of > 5% to ≤ 
55% in LVEF baseline or a reduction of > 10% to ≤ 55% in LVEF without 
accompanying signs and symptoms of HF (12, 15). An expert consensus published 
by the American Society of Echocardiography and European Association of 
Cardiovascular Imaging defines CTRCD as > 10% to < 53% decline in LVEF that 
requires subsequent imaging, within 2-3 weeks, for confirmation (14, 16).   
CTRCD involves functional, structural or a combination of both injuries 
induced by anticancer treatments (17). These injurious events include, but are not 
limited to, cardiomyocyte death, endothelial alteration and ion channel damage; 
which leads to cardiac dysfunction, cardiomyopathies and congestive heart failure 
(6, 17-19).  
Based on the severity and the degree of reversibility, CTRCD is classified as 
type I or type II (14). Type I causes irreversible cardiac toxicity and damage, 
resulting in ultrastructural changes, myofibrillar disarray, myocyte necrosis and 
permeant cardiac dysfunction (20-23). Anthracyclines are an example of type I 
  
3 
 
CTRCD (14, 20, 24). Anthracyclines are a group of anticancer antibiotic (such as, 
daunorubicin, doxorubicin, idarubicin, epirubicin, and mitoxantrone) and are 
effective against various hematological cancers including leukemia and lymphoma, 
as well as solid cancers such as, breast cancer and sarcoma (10, 14, 18). Although 
anthracyclines are effective against cancer, their use is restricted due to the 
associated cardiotoxicity. Left ventricular (LV) dysfunction and HF are some of 
anthracycline-induced complications affecting patients (10). The incidence of 
doxorubicin-induced CHF is dose-dependent. Patients treated with doxorubicin at a 
cumulative dose of 400 mg/m2 are at 3-5% risk of developing CHF, 7-26% risk with 
a dose of 550 mg/m2, 48% risk when receiving a dose of 700 mg/m2 (2, 18, 25, 26). 
Multiple molecular mechanisms have been implicated in anthracycline-induced 
cardiotoxicity, including iron-based oxygen free radical generation, topoisomerase II 
inhibition, mitochondrial dysfunction, and cardiomyocyte apoptosis (6, 10, 11, 14, 
21). 
Contrary to type I, type II CTRCD cardiotoxicity is dose-independent, 
reversible, and is not associated with ultrastructural myocardial abnormalities (20, 
21). This type of toxicity is commonly experienced with trastuzumab, an anti-HER-2 
agent which targets HER-2/neu-positive receptors (known as ErbB2) in breast 
cancer. The mechanism of cardiotoxicity is mediated through inhibiting ErbB2 
signaling cascade required for cardiomyocyte homeostasis, survival, growth, and 
repair (6, 10, 18, 21, 27). Besides trastuzumab, several novel targeted therapies have 
been associated with type II CTRCD, including small molecule tyrosine kinase 
inhibitors (TKIs) (such as, imatinib, sunitinib, sorafenib, and lapatinib) (24, 28, 29). 
Current cancer therapeutics include chemotherapy, radiation, surgical 
resection, immunotherapy and molecular targeted therapy (17). In the last decade, 
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the focus has been shifted towards employing targeted cancer therapies in cancer 
management (30). Targeted therapy with TKIs demonstrates an ability to inhibit 
multiple tyrosine kinases in cancerous cells. However, TKIs also inhibit protein 
kinases present in noncancerous cells, including cardiomyocytes. The nonspecific 
targeting of molecular pathways, which are necessary for cardiac function, could 
result in undesirable cardiovascular adverse effects (31, 32).  
TKIs exhibit two types of toxic effects on cardiomyocytes: on-target and off-
target cardiotoxicity. In “on-target” toxicity, TKIs inhibit signaling pathways that 
are essential to cancer and non-cancerous cell survival and homeostasis. 
Trastuzumab is a classic example of on-target cardiotoxic agent, which exhibits its 
cardiotoxicity by ErbB2 inhibition. “Off-target” toxicity occurs when TKIs inhibit a 
kinase (or a signaling mechanism) not intended to serve as a pharmacological target. 
Sunitinib-induced cardiotoxicity is an example of the off-target cardiotoxic effect, 
which inhibits cytoprotective kinase, ribosomal S6 kinase (RSK), and cellular 
homeostasis regulator, AMP-activated protein kinase (AMPK) (33-37). Although 
the cardiotoxicity induced by radiotherapy and conventional chemotherapy is well-
established (17), the molecular mechanisms governing the cardiotoxicity induced by 
TKIs is not fully understood. An understanding of on-target and off-target 
cardiotoxicity is required for more efficient use of TKIs therapy (38).  
The present research highlights the mechanism of cardiotoxicity associated 
with ponatinib and sunitinib. Ponatinib is a 3rd generation TKI, which is used to treat 
chronic myeloid leukemia (CML) patients, including those harboring T315I 
mutation, and Philadelphia chromosome-positive (Ph+) acute lymphoblastic 
leukemia (ALL) (39). Whereas, sunitinib is a multi-tyrosine kinase inhibitor, which 
was first approved for advanced renal cell carcinoma (RCC) and currently is used 
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additional indications, including gastrointestinal stromal tumor (GIST) and 
pancreatic cancer (40). This chapter seeks to address ponatinib and sunitinib and 
their main indications, CML and RCC, respectively, and focuses on delineating the 
mechanism of cardiotoxicity associated with ponatinib and sunitinib.  
1.3. Chronic Myeloid Leukemia (CML): Epidemiology, Pathophysiology, and 
Management  
CML is a myeloproliferative neoplasm characterized by a unique molecular 
pathophysiology and clinical manifestation (41, 42). According to global cancer 
statistics, in 2013, there were 414,000 incident leukemia cases worldwide and 
265,000 incident deaths among leukemic patients (43). In 2000, the prevalence of 
CML, in the United States (US), was estimated at 30,000 cases, then increased, in 
2017, to 100,000 cases and is predicted to reach a plateau at 180,000 CML cases by 
2030 (41).  
CML affects the hematopoietic stem cells. Central to its pathogenesis is the 
reciprocal translocation between the ABL (Abselon murine leukemia) gene, a non-
receptor tyrosine kinase expressed in several tissues, on chromosome 9, and the 
BCR gene (breakpoint cluster region) on chromosome 22, t(9;22) (q34;q11), known 
as Philadelphia chromosome. The resulting chimeric fusion gene, known as BCR-
ABL, encodes a constitutively active protein tyrosine kinase and is a key to disease 
development, detection, and monitoring and also serves as a target for newly 
developed therapeutics (44-49). 
At a molecular level, BCR-ABL oncoprotein promotes cellular proliferation, 
survival, growth and maintenance of CML leukemogenesis through interaction with 
numerous intracellular signaling molecules such as, RAS/mitogen-activated protein 
kinase (MAPK), phosphatidylinositol 3 kinase (PI3K)/AKT, signal transducer and 
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activator of transcription-5 (STAT5), mammalian target of rapamycin (mTOR), Src 
kinases, Jun, and Myc (41, 42, 50-54). Clinically CML exists in three phases, 
starting with a chronic phase, progressing into an unstable stage known as 
accelerated phase, and transitioning to a terminal phase known as blast phase or 
blast crisis (42, 47, 49).  
The advent of TKIs has dramatically changed CML management with a 10-
year survival rate exceeding 80%. Prior to the development of TKIs, CML 
management relied on either palliative therapy, including spleen irradiation and 
cytoreductive agents (such as, arsenic, busulfan and hydroxyurea) or curative 
therapy, including interferon-α and allogeneic stem-cell transplantation (45, 54). 
However, these modalities were associated with few drawbacks; cytoreductive 
agents possess palliative but not curative effect, while interferon-α is poorly 
tolerable and allogenic stem-cell transplantation is associated with high morbidity 
and mortality (54). In 2003, IRIS study (International Randomized Study of 
Interferon-α and low-dose cytarabine versus STI571) proved the superiority of 
STI571 (now known as imatinib) in comparison with combination therapy in newly 
diagnosed chronic phase CML patients (55).  
Despite the breakthrough results of IRIS study, follow-up studies have shown 
high rates of discontinuation due to intolerance and/or primary and acquired 
resistance to imatinib treatment (47, 56). This resistance is due to the amplification 
of BCR-ABL oncogene, upregulation of multidrug resistant p-glycoprotein, down 
regulation of OCT-1 influx transporter, and/or single amino acid mutation (point 
mutation) on BCR-ABL kinase domain, which limits TKIs binding (44, 47). Shortly 
after imatinib introduction, second-generation TKIs, dasatinib, nilotinib, and 
bosutinib, were developed to manage imatinib-resistant CML (54, 56). However, 
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second-generation TKIs lack sensitivity against BCR-ABL T315I point mutation 
(57). T315I gatekeeper mutation is among the frequent point mutations in CML, 
accounting to 2-20% cases. This mutation is resistant to a broad-spectrum of TKIs 
and is only inhibited by a third-generation agent, ponatinib (44, 58). 
1.3.1. Ponatinib 
Ponatinib is a small molecule, orally active, and potent BCR-ABL inhibitor 
against numerous domain mutations, including T315I gatekeeper mutation (54, 56, 
58) (Figure 1.1). In CML, ponatinib induces its anti-proliferative and anti-survival 
effects by inhibiting BCR-ABL oncoprotein and its downstream signaling molecules 
(Figure 1.2) (53, 54). Besides BCR-ABL, ponatinib effectively inhibits up to 40 
kinases, including, SRC, PDGFR (platelet-derived growth factor receptor), FGFR 
(fibroblast growth factor receptor), VEGFR 1-3 (vascular endothelial growth factor 
receptor 1-3), RET (rearranged during transfection), KIT, AKT, ERK (extracellular 
signal-regulated kinase), and FLT1/3 (FMS-like tyrosine kinase-1 and 3) and other 
kinases (59-61). 
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Figure 1.1 Chemical structure of ponatinib, free base. Ponatinib is 3-(2-
imidazo[1,2b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-
piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-benzamide (59, 62). 
 
 
 
Figure 1.2 Mechanism of action of ponatinib. The novel tyrosine kinase inhibitor, 
ponatinib, exerts its activity by inhibiting BCR-ABL oncoprotein and its downstream 
effectors, thereby decreasing leukemic cell proliferation and survival. This figure was 
adapted from Dao et al. (2013) and Pophali et al. (2016) (53, 54).   
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1.3.1.1. Ponatinib-Induced Cardiotoxicity 
In 2012, due to promising results from a phase II PACE study (Ponatinib Ph+ 
ALL and CML Evaluation), ponatinib was granted an accelerated approval as a 
treatment for CML patients with resistance or intolerance to previous TKI therapies 
(54, 63, 64). However, ponatinib was associated with increased incidence of 
cardiovascular issues. At a median follow-up of 28 months, PACE trial reported 
10% cardiovascular, 7% cerebrovascular, 7% peripheral arterial, 19% arterial 
thrombotic, and 5% venous thromboembolic events (65). In addition, it was reported 
that 26% of patients developed systemic hypertension, which is probably attributed 
to VEGFR inhibition by ponatinib (61, 65). Due to concerns of heart failure and 
vascular occlusive events, ponatinib was temporarily withdrawn from the US market 
by the Food and Drug Administration (FDA) and was reintroduced to the market in 
2014 (60, 64, 66).   
Cardiovascular toxicity is an alarming concern with the new BCR-ABL TKIs, 
including ponatinib; however, it is uncommon with imatinib. In fact, imatinib 
demonstrates beneficial cardiovascular effects, improved cardiac function and 
enhanced exercise capacity in patients with pulmonary arterial hypertension (67, 
68). In addition, a retrospective cohort analysis showed lower incidence of 
peripheral arterial occlusive disease events in CML patients receiving imatinib than 
those receiving nilotinib or not treated with TKIs (69). Given the fact of lower 
cardiovascular toxicity of imatinib, it is probable, therefore, that ponatinib-induced 
cardiovascular toxicity is an off-target effect and not necessarily an on-target effect 
(61).  
Although ponatinib-induced cardiovascular toxicity and dysfunction is well-
recognized, the molecular mechanism behind cardiotoxicity remains unclear (70). 
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One known mechanism of cardiotoxicity is through inhibition of VEGFR1-3, which 
is associated with increased incidences of hypertension (similar to vascular signaling 
pathway inhibitor, sunitinib) via increased endothelin-1, as well as reduced nitric 
oxide (NO), or reduced density of capillaries (66, 71, 72).  
Several studies have investigated ponatinib-induced cardiotoxicity on different 
in vitro and in vivo models. In a study that used a cell-based model, human induced 
pluripotent stem cell–derived cardiomyocytes, endothelial cells and cardiac 
fibroblasts (hiPSC-CMs, hiPSC-ECs, hiPSC-FCs, respectively) for high-throughput 
cardiotoxicity screen of 21 TKIs, it was found that ponatinib led to remarkable cell 
death in hiPSC-derived cell models (73).  In agreement, another study found that 
treatment with 5µM and 10µM ponatinib lead to significant reduction in hiPSC-CMs 
cell viability (74). Moreover, a previous study demonstrated a significant neonatal 
rat ventricular cardiomyocytes (NRVMs) damage following treatment with 2µM 
ponatinib. Authors found that ponatinib-treated NRVMs exhibits morphological 
disruption of sarcomeres, myofibril loss, and reduction of myocyte cellular density. 
In this study, authors found that ponatinib-induced cardiotoxicity may be an on-
target effect (ABL inhibition) and/or an off-target effect (other protein kinases) (75). 
Furthermore, recently, Singh et al. studied the cardiotoxicity of CML-approved 
TKIs, including dasatinib, imatinib, ponatinib, nilotinib, and bosutinib using 
zebrafish and NRVMs. Investigators indicated ponatinib as the most toxic agent, 
among all screened TKIs, to zebrafish in vivo model. In addition, they found that 
treatment with 50nM ponatinib induced AKT and ERK prosurvival inhibition which 
is central to NRVMs apoptosis. Authors observed that other CML-TKIs could not 
suppress AKT-ERK pathway; indicating that it is a distinctive effect induced by 
ponatinib. Moreover, authors found that pretreatment of NRVMs with Neuregulin-
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1β (a PI3K/AKT and ERK pathways inducer) is able to significantly reduce 
ponatinib-induced cardiomyocyte death. (76). Figure 1.3 is a summary of a proposed 
model of known mechanisms governing ponatinib-induced cardiotoxicity, which 
may predispose to cardiac dysfunction. Taken together, it is evident that 
ponatinib treatment is associated with cardiotoxicity. Hence, it is critical to 
identify the potential mechanisms of cardiotoxicity induced by ponatinib, in 
order to develop preventative strategies and to optimize patients care. Herein, 
we focused on investigating two potential mechanisms of cardiotoxicity, ribosomal 
S6 Kinase and autophagy alteration, which will be discussed in the upcoming 
sections.  
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Figure 1.3 Summary of a proposed model of molecular mechanisms of ponatinib-
induced cardiotoxicity. Treatment with ponatinib is associated with cardiotoxic 
effects that may be mediated through an on-target and off-target mechanism. 
Ponatinib inhibits VEGFR1-3, which induces systemic hypertension. Another 
cardiotoxic mechanism of ponatinib involves the inhibition of AKT/ERK 
prosurvival pathway and caspase-dependent apoptotic cell death. These cardiotoxic 
effects induced by treatment with ponatinib may predispose to cardiac dysfunction 
(66, 71, 76).  
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1.4. Renal Cell Carcinoma (RCC): Epidemiology, Pathophysiology, and 
Management 
Renal cell carcinoma (RCC) or kidney cancer comprises of a heterogeneous 
group of chemotherapy-resistant cancers that can be distinguished by distinct 
histopathological features, molecular characteristics, and genetic abnormalities (77, 
78). In 2013, RCC was ranked the 16th most common cause of cancer worldwide and 
the 10th common cancer in developed countries (43). Globally, in the same year, a 
total of 295,000 incident cases and 134,000 incident deaths from kidney cancer were 
reported. In the US, in 2016, the kidney cancer incidence and death were estimated 
to be 62,700 and 14,240 cases, respectively. The median age at diagnosis was 
estimated to be 64 years with an estimated 5-year relative survival rate that stands at 
73% (79, 80).  
Histologically, RCC can be classified into clear cell RCC (ccRCC), papillary 
RCC (pRCC) and chromophobe RCC (chRCC). ccRCC is the most common 
subtype, originating in the proximal tubule and accounting for 80% of all RCC cases 
(81-84). Central to ccRCC carcinogenesis is the biallelic loss of function of von 
Hippel-Lindau (VHL) tumor suppressor gene, which leads to stabilization of 
hypoxia-inducible factors (HIF-1 and HIF-2) and activates downstream genes, 
including VEGF and PDGF; leading to increased cellular growth, survival, and 
angiogenesis. Moreover, mutations of epigenetic regulators (like, Polybromo-1 
(PBRM-1), along with BRCA-associated protein-1 (BAP-1)), abnormalities of 
chromatin remodeling genes (SET domain containing-2 (SETD-2)), and mutations 
involving mTOR signaling pathway (PTEN, PI3K, AKT, and mTOR) is a 
characteristic feature of ccRCC (77, 78, 82, 84, 85).  
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In the past, RCC was considered as a chemotherapy-resistant condition. 
Interferon-α and interleukin-2 were used as standard therapy for metastatic RCC. 
Due to low response and survival rate and high adverse effects, their use was 
limited. Nonetheless, the basic understanding of disease etiology and development 
of antiangiogenic agents targeting VEGF and VEGFR, immune checkpoint 
inhibitors and mTOR inhibitors have led to a substantial improvement in RCC 
treatment and clinical outcomes. Sunitinib is a multitargeted TKI, which inhibits 
multiple factors and receptors, including, but not limited to, VEGFR and PDGFR 
and is commonly used as a first-line agent (40, 77, 78, 82, 85). 
1.4.1. Sunitinib 
Sunitinib is an orally active small molecule multi-tyrosine kinase inhibitor 
(Figure 1.4). It potently inhibits VEGFR 1-3, PDGFR-α and β, FLT-3, and stem cell 
factor receptor (c-KIT), and RET. Inhibition of these tyrosine kinases blocks 
multiple signaling pathways, including PI3K/AKT, MAPK, and protein kinase C, 
thereby triggering anticancer effects by inhibiting tumor progression, proliferation, 
and angiogenic effects, and promoting vascular disruption (Figure 1.5) (32, 71, 86-
89). 
Sunitinib has been approved as a first-line treatment for advanced RCC and as 
a second-line treatment for GIST (32, 87). Motzer et al. compared between sunitinib 
and Interferon-α in patients with untreated RCC and found that sunitinib was 
superior to Interferon-α. In this trial, the progression-free survival was longer (11 
months vs 5 months, respectively, P < 0.001) and the response rate was higher in 
sunitinib arm (86, 90). Sunitinib treatment was associated with adverse events 
including, fatigue, hand-foot syndrome, nausea, diarrhea, cardiovascular events (86, 
90). Whilst sunitinib has improved the clinical outcomes of RCC cancer patients, its 
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therapeutic use is limited due to its associated cardiotoxicity (91). Therefore, 
understanding the mechanisms of sunitinib-induced cardiotoxicity is critical to 
identifying preventative strategies. 
 
 
Figure 1.4. Chemical structure of sunitinib, free base. Sunitinib is N-
[2(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-
ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide (92). 
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Figure 1.5. Mechanism of action of sunitinib. Sunitinib inhibits multiple tyrosine 
kinases such as, PDGFR- and , KIT, RET, FLT3, and VEGFR1-3. As a result, 
sunitinib inhibits several signaling pathways, including RAS/mitogen-activated 
protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)/AKT, and Protein Kinase 
C, thereby triggering antitumor effects by blocking tumor progression and angiogenic 
effects and promoting vascular disruption. This figure was adapted from Faivre et al. 
(2007) and Aparicio-Gallego et al. (2011) (88, 89). 
 
 
1.4.2. Sunitinib-Induced Cardiotoxicity  
Cardiovascular safety profile of sunitinib has received a growing attention 
following multiple clinical studies (93). Sunitinib use has been associated with 
multiple cardiovascular adverse effects including, hypertension, decline in LVEF, LV 
systolic dysfunction, myocardial infarction and heart failure (71, 87, 90, 94). A phase 
III randomized, double blinded, trial patients with GIST showed incidence of 
  
17 
 
reduction in LVEF by 11% in sunitinib arm versus 3% in placebo arm (93, 95). 
Another study, involving patients treated with sunitinib for metastatic ccRCC, showed 
that 4.7% of patients experienced declines in LVEF (96). In a meta-analysis 
consisting of 13 clinical trials and a total of 4999 patients, it was reported that the 
incidence of all-grade hypertension among patients treated with sunitinib were 21.6% 
(71). Although sunitinib-induced cardiovascular toxicity is well-recognized, the 
underlying mechanisms of cardiotoxicity are not fully understood.  
At a cellular level, Chu et al. have shown that sunitinib-induced cardiac 
dysfunction is characterized by cardiomyocyte abnormalities, mitochondrial swelling 
and activation of apoptosis (94). This observation could be attributed, in part, to the 
inhibition of PDGFR-β, which is involved in angiogenic regulation of cardiomyocyte 
response to pressure overload. Chintalgattu et al. have found that absence of PDGFR-
β in cardiomyocytes led to impaired angiogenesis, myocardial dysfunction and heart 
failure (87, 97). In addition, sunitinib inhibits VEGFR1-3, which leads to systemic 
hypertension and heart failure. This is due to reduction of NO production (32, 98).  
Another mechanism of sunitinib-induced cardiotoxicity involves the inhibition 
of AMPK signaling, which leads to mitochondrial dysfunction, ATP depletion and 
apoptosis. AMPK plays an indispensable role during energy depleted conditions; it 
regulates energy utilization and activates energy generation pathways. Through 
inhibition of AMPK by sunitinib, cells lose energy by blocking energy-generating 
mechanisms and activating energy-consuming mechanisms. Also, inhibition of 
AMPK by sunitinib along with inhibition of VEGFR and PDGFR decrease adaptation 
to cardiac stress (31, 32, 87, 99, 100). Other suggested mechanisms of sunitinib-
mediated cardiotoxicity involve RSK inhibition and activation of autophagy, (31, 38, 
100, 101), which will be highlighted in the following sections of this chapter. Figure 
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1.6 is a summary of a proposed model of some mechanisms governing sunitinib-
induced cardiotoxicity, which may predispose to cardiac dysfunction. 
 
 
 
Figure 1.6. Summary of a proposed model of molecular mechanisms of sunitinib-
induced cardiotoxicity. Treatment with sunitinib is associated with cardiotoxic effects 
that may be mediated through an on-target and off-target mechanism. A postulated 
mechanism of sunitinib-induced involves the inhibition of VEGFR1-3 and PDGFR, 
which causes systemic hypertension and decreases adaptation to cardiac stress. Also, 
sunitinib treatment induces cardiomyocyte caspase-dependent apoptotic cell death 
through inhibiting prosurvival RSK pathway. Another mechanism of sunitinib-
induced cardiotoxicity involves the inhibition of AMPK, which decreases adaptation 
to cardiac stress, causes ATP depletion, and leads to mitochondrial dysfunction. 
Sunitinib has also shown to induce autophagic flux in cardiomyocyte. This figure was 
adopted from Gorini et al. (2018) (31). 
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1.5. Speculated Molecular Mechanisms of Sunitinib and Ponatinib-Mediated 
Cardiotoxicity 
1.5.1. Ribosomal S6 Kinase (RSK) 
The Ras-MAPK pathway plays an indispensable role in regulating different 
cellular processes (102-104). Various extracellular stimuli, including 
neurotransmitters, hormones, growth factors, and chemokines stimulates receptor 
tyrosine kinase (RTK) autophosphorylation. This leads to activation of adaptor 
proteins, such as growth factor receptor-bound protein 2 (GRB2), son of sevenless 
(SOS), and activation of Ras and Raf protein kinases. Raf then phosphorylates 
MEK1/2 (MAPK-extracellular signal-regulated kinase 1/2) and ERK1/2. Downstream 
to this pathway is a 90 kDa family of highly conserved serine-threonine (Ser/Thr) 
proteins, ribosomal S6 kinases 1-4 (RSK1-4), which are directly and exclusively 
phosphorylated by ERK1/2 (Figure 1.7). RSK isoforms are ubiquitously expressed in 
many cell lines and tissues; RSK1 is expressed in the brain, lung, kidney, and 
pancreas. RSK2 and 3 are expressed in the brain, heart, and pancreas (102, 105, 106). 
Various pan-RSK inhibitors exist, including competitive inhibitors (SL0101 and BI-
D1870), which target the ATP-binding site of the amino terminal kinase domain 
(NTKD), and irreversible inhibitor (fluoromethyl ketone (FMK)), which targets the 
cysteine residue-ATP-binding site of the carboxyl-terminal kinase domain (CTKD) 
(105, 107). 
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1.5.1.1. Role of RSK in Cellular Processes  
Based on the nature of RSK substrates, several roles can be deduced; RSK 
regulates multiple processes, including cellular growth, survival, proliferation, and 
cell cycle progression (104-106, 108). Activated RSK has been shown to 
phosphorylate numerous transcription factors that induce immediate-early (IE) gene 
expression, including cAMP response element-binding protein (CREB), serum 
response factor (SRF), nuclear factor-kB (NF-kB), transcription initiation factor 
TIF1A, ETS translocation variant-1, and cytoplasmic nuclear factor of activated T-
cells 4 (NFATc4), and estrogen receptor-a. In addition, RSK can phosphorylate IE 
gene products, including c-Fos, c-Jun, and nuclear receptor subfamily (Nur77) (102-
105, 109). In addition, RSK has been implicated in protein synthesis and cell growth 
through the phosphorylation of tuberous sclerosis complex 2 (TSC2) and Raptor, 
which stimulate mTOR signaling (110, 111). Moreover, RSK phosphorylates and 
inhibits GSK3 (Glycogen synthase kinase 3), which causes stabilization of Myc-c and 
cyclin D1 and mediates cell cycle progression and survival (112, 113). Further, RSK 
regulates protein synthesis through stimulating the translation initiation protein, eIF4B 
(114). Also, RSK regulates cell survival through 1) the inactivation of death-
associated protein kinase (DAPK), a pro-apoptotic and tumor suppressor protein (115) 
and 2) reduction of pro-apoptotic activity of BCL-2-associated death promoter (BAD) 
(116). Another role of RSK involves regulating cell cycle through participating in G1-
phase progression by phosphorylating cyclin-dependent kinase inhibitor p27kip1 (117), 
and in G1-S phase progression by activating c-Fos (102, 118).  
Taken together, RSK, as a downstream effector of Ras-MAPK pathway, is 
implicated in various critical cellular processes. Aberration or mutation in genes 
encoding Ras-MAPK pathway constitutes have been implicated in several 
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pathologies, including cancer, cardiovascular diseases, diabetes, inflammatory and 
neurodegenerative disorders (102, 104, 108, 119). Herein, we focused on the role of 
RSK in cancer and cardiac pathophysiology. 
 
 
Figure 1.7. Illustration of ribosomal S6 kinase (RSK) activation. 
 
 
1.5.1.2. RSK and Cancer  
RSK is an important Ras-MAPK effector and attracted considerable interest as 
a potential target for multiple cancer therapies. Dysregulated RSK activity has been 
implicated in various forms of cancer. RSK1 and RSK2 have been implicated in 
cancer progression through mediating tumor cell survival and growth (105, 108). 
They promote pro-survival and reduce pro-apoptotic genes through phosphorylation 
of CREB, BAD, DAPK, and BimEL (115, 116, 120, 121). In addition, they 
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phosphorylate TSC2 and raptor, stimulating mTOR pathway and promoting cell 
growth (110, 111). Moreover, RSK1 and RSK2 were shown to inhibit GSK3 and 
phosphorylate c-Fos and p27kip1, promoting cell proliferation (102, 107, 117). 
Furthermore, they reduce cell adhesion and promote tumor invasion and metastasis 
through phosphorylating SH3 domain-containing protein (SH3P2) (122), FRA1 (123, 
124), c-Jun (123, 124), and filamin A (125), as well as inactivating the integrin 
activation (126). Contrary to RSK1 and RSK2, both RSK3 and RSK4 were shown to 
act as tumor suppressors (102). Overall, it is notable that RSK is involved in cancer 
pathophysiology through direct and indirect molecular mechanisms.   
1.5.1.3. RSK and Cardiovascular Diseases  
In the heart, RSK has an imperative role in cardiac physiology, where its 
aberrant activity is correlated with cardiac hypertrophy and heart failure. Increased 
RSK activity was previously detected following hypertrophic stimulation of cardiac 
myocytes and fibroblasts and in failing hearts of patients with end-stage dilated 
cardiomyopathy (127, 128). Takeishi et al. found that p90RSK is activated under 
ischemia/reperfusion (I/R) condition in guinea pigs (129). In addition, it was shown 
that Na+/H+ exchanger 1 (NHE1)-p90RSK activation promotes cardiomyocyte 
hypertrophy (130). Moreover, Yamaguchi et al. found that activated p90RSK 
decreases GSK3 and promotes cardiac hypertrophy in mice expressing aberrant type 2 
ryanodine receptor ion channel (131). Further, stimulation of p90RSK via 
prostaglandin E2 in neonatal ventricular myocytes was shown to induce c-Fos, brain 
natriuretic peptide (BNP), and early growth response 1, promoting myocyte growth 
and possibly cardiomyocyte hypertrophy (132).  
In addition to cardiac hypertrophy, activated p90RSK was shown to inhibit 
voltage-gated K+ channel activity, prolonging the cardiac QT intervals, and 
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predisposing the heart to arrhythmias (133).  
Furthermore, during atherosclerosis, p90RSK is activated, resulting in 
phosphorylation of small ubiquitin-like modifier-specific protease-2 (SENP2) and 
promotes SENP2 nuclear export. P90RSK-mediated SENP2 nuclear export induces 
endothelial cell apoptosis, inflammation, endothelial NO synthase (eNOS) reduction, 
and formation of atherosclerosis plague (134, 135). Le et al. found that p90RSK 
inhibitor induced anti-atherosclerosis effects by decreasing the expression of adhesion 
molecule and increasing expression of eNOS (136). Overall, these findings confirm 
the complex role of RSK in the pathophysiology of cardiovascular diseases. 
1.5.1.4. RSK in TKIs-Induced Cardiotoxicity 
Role of RSK in cardiovascular toxicity is paradoxical. Recently, it was shown 
that ponatinib upregulates p90RSK protein expression in human endothelial cell 
lines (137). This activation plays a role in endothelial cell death and formation of 
atherosclerotic lesions. However, whether ponatinib induces p90RSK in 
cardiomyocyte model is not yet known. In a previous study, the biochemical 
inhibitory activity of 313 kinases was screened using 1µM of 25 kinase inhibitors. 
Treatment with 1µM ponatinib has weakly inhibited RSK1, 2, 3, and 4 by 32%, 
30%, 62%, and 13%, respectively (138).  
Conversely, inhibition of RSK activity has been a postulated mechanism of 
cardiotoxicity induced by sunitinib. It was previously demonstrated that treatment 
with 1µM sunitinib is able to potent inhibition RSK1-4 by 95-97% (138). In 
addition, Karaman et al. screened 38 kinase inhibitors, including 21 TKIs, against a 
panel of 317 protein kinases and determined the binding dissociation constant (Kd) 
for each interaction. Based on kinase map interaction, they found that the Kd for 
RSK1 following 10µM treatment with sunitinib was 0.14µM, Kd for RSK2 was 
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0.017µM, and Kd for RSK3 was 0.58µM (35). As a result, Force et al. hypothesized 
that sunitinib-induced cardiotoxicity is via the inhibition of RSK signaling pathway, 
which would lead to release of the pro-apoptotic factor BAD, subsequent activation 
of BCL2-associated X protein (BAX), and release of cytochrome c, resulting in the 
activation of apoptosis and ATP depletion. Activated apoptosis would promote 
cardiomyocyte loss, which along with ATP depletion would cause LV dysfunction 
and mediate cardiac hypertrophy (Figure 1.6) (38). As a proof of concept, Hasinoff 
et al. studied whether sunitinib inhibits RSK, promotes myocyte damage, and 
induces cellular death. Authors found that treatment of NRVMs with sunitinib 
inhibited RSK1 with a half maximal inhibitory concentration (IC50) of 0.36µM. In 
addition, it was shown that sunitinib treatment increased caspase-3/7 activity without 
change in BAX activity (100). These findings demonstrate that ponatinib is an 
inducer of p90RSK activity whereas sunitinib is a potent inhibitor. Therefore, it is 
important to delineate the exact role of RSK in ponatinib-mediated cardiotoxicity. 
1.5.2. Autophagy  
Autophagy, from the Greek word “self-eating”, is described as a highly 
conserved cellular pathway in eukaryotes. It involves degrading and recycling of 
intracellular components to maintain cellular homeostasis and to eliminate misfolded 
proteins and damaged organelles. During autophagy, cytoplasmic components are 
delivered to lysosome and then degraded or recycled to active monomers (139, 140).  
Autophagy is classified into three types: chaperone-mediated (CMA), 
microautophagy and macroautophgy. Macroautophagy is the most prevalent 
autophagic pathway, hereafter termed autophagy, involves the formation of a double 
membrane structure, termed autophagosome, that engulfs the intracellular 
components, and then fuses with the lysosomes for degradation (141). Autophagy is 
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regulated by a number of highly conserved Atg (Autophagy) genes and serves as 
regulator for several physiological and pathological processes (142). Although 
autophagy occurs at basal conditions, it can be triggered by various stimuli including, 
nutrient-depletion conditions, oxygen insufficiency, and hormones (143, 144).  
1.5.2.1. Monitoring Autophagy 
There are several methods to monitor autophagy, including measurement of 
autophagosome abundance by immunoblotting, measurement of long-lived protein 
degradation by electron microscopy, quantification of autophagic flux in the presence 
and absence of autophagy inhibitors, and utilization of microtubule-associated protein 
1 light chain 3 (LC3) fluorescent probe to quantify autophagic flux (145, 146).  
Under physiological conditions, the microtubule-associated protein 1 light 
chain 3 (LC3) exists as LC3-I (cytosolic form). Once autophagy is activated, LC3 is 
conjugated to phosphatidylethanolamine and lipidated to form LC3-II, which is 
recruited to the inner and outer autophagosomal membrane (147, 148). Measuring the 
amount of LC3-II expression by immunoblotting is a commonly-used indicator of the 
number of autophagosome and autophagic structure. However, LC3-II is not an 
appropriate marker of autophagic activity, as LC3-II accumulation could reflect 
induction of autophagosome formation and/or aberrant autophagosome degradation. 
Therefore, to evaluate the autophagic activity, it is critical to monitor the autophagic 
flux using autophagy inhibitors (such as, chloroquine, bafilomycin, and pepstatinA) 
(145, 146, 148, 149).  
Another widely used method to monitor autophagic flux involves assessing 
p62 degradation (148). Degradation of p62 is directly dependent on autophagy; it 
accumulates when autophagy is blocked and decreases when autophagy is induced 
(150). 
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1.5.2.2. Role of autophagy in Cellular Processes 
Although autophagy is robustly activated upon starvation, under normal 
conditions, autophagy occurs at basal rate to maintain the cellular homeostasis and the 
integrity of macromolecules and organelles. This is through eliminating unneeded, 
damaged, or misfolded proteins and organelles and preventing protein aggregates and 
pathogens (145, 151, 152).  
Activated autophagic processes, in times of metabolic stress including, 
nutrient deprivation, hypoxia, and growth factor reduction, is thought to play an 
adaptive role. In nutrient deprivation condition, autophagic degradation generates 
amino acids and free fatty acids that are used for the de novo synthesis of proteins and 
ATP production (152, 153). In case of oxygen deficiency, autophagy is induced by 
HIF-1α through increasing Bcl-2/E1B-interacting protein 3 (BNIP3), protecting 
against cell damage. BNIP3 activates autophagy through releasing BCL-2 and BCL-
XL-bound Beclin1 (154).  
Autophagy exhibits cytoprotective effects; its inhibition promotes type I cell 
death (apoptotic cell death). Boya et al. have shown that inhibition of autophagy by 
interfering RNA or using pharmacological inhibitors induces apoptotic type of cell 
death (155). Since autophagy plays a critical role in homeostasis, its dysregulation has 
been implicated in several pathologies, including neurodegenerative disorders, cancer, 
and cardiac dysfunction (139, 152, 156).  
1.5.2.3. Autophagy and Cancer  
The role of autophagy in cancer is paradoxical. Based on a number of factors, 
for example, tumor type, autophagy could have prosurvival or pro-death roles. Such 
contrasting dual roles of autophagy has been reported with Ras and p53 proteins, 
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frequently mutated in human cancer (157, 158).  
Since aberrant autophagy was implicated in tumorigenesis, it was initially 
thought to have a tumor-suppressive role (159, 160). Beclin1, an autophagy gene, can 
suppress tumor formation; lower expression level of Beclin1 was observed in human 
breast cancer cells compared with higher expression level in normal breast epithelia 
(142, 161). Moreover, tumor suppressor phosphatase and tensin homolog (PTEN), 
frequently mutated in variety of cancers, was shown to promote autophagy (162, 163). 
These findings demonstrate that autophagy is not only implicated in tumor-
suppression, but it could also promote tumor formation.  
Autophagy promotes tumor progression by protecting tumor cells from 
necrosis and fulfilling their elevated metabolic demands (159, 160). Hypoxic 
microenvironment stimulates HIF-1-induced autophagy and promotes tumor 
survival (164). Autophagy demonstrates a complex role in cancer. Therefore, 
understanding the mechanism of autophagy in cancer setting is required as it may 
serve as a potential tumor-suppressive target.   
1.5.2.4. Autophagy and Cardiac Diseases   
In myocardium, autophagy is thought to maintain normal cardiac structure and 
function; its inhibition or absence leads to cardiac hypertrophy and other cardiac 
pathologies (165). A growing body of evidence suggests that autophagy is induced in 
various heart diseases including, heart failure, cardiac hypertrophy, and myocardial 
I/R (166-168). Autophagic response is thought to act as a protective mechanism 
against ischemia-induced cardiac remodeling and dysfunction. Matsui et al. found that 
ischemia, due to glucose deprivation, stimulated autophagy through activating AMPK 
and inhibiting mTOR. Whereas reperfusion was accompanied by an increase of 
Beclin1 (166). In addition, Ma et al. found that autophagy was induced following I/R 
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in cardiomyocytes; however, autophagosome clearance was compromised, which led 
to cardiomyocyte death. Authors have found that the mechanism of cardiomyocyte 
death was through decreased lysosome-associated membrane protein-2 (LAMP2), 
upregulated Beclin1 and reactive-oxygen species (ROS) generation, and 
mitochondrial damage (169).  
Unlike ischemia injury, autophagy-induced due to pressure overload could 
manifest as maladaptive and lead to detrimental effects to the heart. Zhu et al. found 
that the autophagy-induced, in cardiomyocytes, in response to pressure overload is 
through the upregulation of Beclin1. They also found that cardiac remodeling is 
reversed through inhibition of autophagy via heterozygous knockdown of Beclin1 
(143). Moreover, Porrello et al. found that neurohormonal stimulation with 
angiotensin II (ANG II) upregulates autophagy in neonatal cardiomyocytes through 
ANG II type I receptor (AT1R), whereas ANG II type II receptor (AT2R) 
demonstrated anti-autophagic activity (170).  
Dysregulated myocardial autophagy could result in age-related 
cardiomyopathy, cardiac hypertrophy, and heart failure. A previous study showed that 
cardiac specific Atg5-deficient mice, led to ventricular dilatation and dysfunction with 
increasing age (171). Moreover, Nakai et al. have found that cardiac specific Atg5-
deficient mice promoted cardiac hypertrophy, LV dilatation, and cardiac dysfunction. 
Besides, Atg5-deficient heart showed disrupted sarcomere structure. Authors have 
examined the role of autophagy in neonatal cardiomyocyte; they demonstrated that 
Atg7 knockdown promote significant cardiac hypertrophy. Authors also suggested 
that basal autophagy is involved in maintaining homeostasis while upregulated 
autophagy, in failing heart, protects cardiomyocyte from hemodynamic stress (165). 
Furthermore, deficiency of LAMP2 causes Danon disease, which exhibits 
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accumulation of autophagic vacuoles and leads to heart failure (168, 172). Together, 
these findings show the different roles of autophagy in cardiac pathogenesis. Apart 
from its roles in cancer and cardiac diseases, autophagy has been implicated in TKIs-
induced cardiotoxicity (146).   
1.5.2.5. Autophagy in Small Molecule TKIs-Induced Cardiotoxicity 
Many TKIs modulate autophagy in several types of tumor and non-tumor cells 
(146). For example, it was shown that imatinib induces cellular autophagy in 
mammalian cells (173). In isolated neonatal cardiomyocytes, it was found that 
imatinib induces cardiotoxicity by accumulating in lysosomes and disrupting 
autophagy. Authors found that imatinib increased LC3-II expression and increased 
p62 abundance, secondary to impairment of autophagy (174). In addition, autophagy 
was shown to play a role in sunitinib-induced cardiomyoblast loss. Exposure of H9c2, 
cardiomyoblast, cells to sunitinib increased LC3-II protein expression. Although 
autophagic flux was not assessed, the study showed that Beclin1 knockdown 
decreased H9c2 cell death associated with sunitinib treatment (101). A recent study 
found that sunitinib induced autophagic flux in H9c2 cardiomyoblast. Authors were 
able to attenuate sunitinib-induced cardiotoxicity by pretreatment with geldanamycin, 
a heat shock-protein 90 (Hsp90) inhibitor, which inhibited autophagy induction (175). 
Overall, these findings show that autophagy may play a role in TKIs-induced 
cardiotoxicity. However, Further studies are necessary to confirm the exact role of 
autophagy in ponatinib-mediate cardiotoxicity.   
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1.6. Thesis Rationale, Hypothesis and Objectives 
1.6.1. Rationale 
In recent years, the anticancer modalities have shifted towards a targeted 
approach which has remarkably prolonged the survival rates of cancer patients. 
Among the newly targeted anticancer therapies are TKIs. Although cancer prognosis 
has dramatically improved with TKIs, their use has been associated with undesirable 
cardiovascular toxicity. Cardiotoxicity is a well-known complication arisen during 
and/or after treatment with TKIs. Despite the high incidence of cardiotoxicity and the 
efforts to tackle it, the etiology remains unclear. Therefore, it is necessary to 
understand the molecular mechanisms of cardiotoxicity induced by TKIs, in order to 
inhibit or reverse their cardiotoxic effects without reducing TKIs efficacy.  
Sunitinib and ponatinib are potent 2nd and 3rd generation TKIs used for the 
treatment of RCC and CML, respectively. Multiple signaling molecules have been 
implicated in sunitinib and ponatinib-induced cardiotoxicity. One of those 
mechanisms involves modulation of RSK. It was postulated that sunitinib induces 
cardiotoxic effects (such as, cardiomyocyte loss and hypertrophy) through inhibiting 
RSK activity. In human endothelial cells, ponatinib increased the phosphorylation of 
p90RSK expression, which probably mediates atherosclerotic effects. However, 
whether ponatinib induces or inhibits RSK in the cardiac setting is still unknown.  
Besides RSK modulation, induction of autophagy plays a role in TKIs-induced 
cardiotoxicity. Autophagy was shown to mediate cardiomyocyte cell death following 
sunitinib treatment, which was rescued by autophagy inhibition. Whether the same 
effect is observed following ponatinib treatment in remains unclear. Hence, this study 
investigates RSK and autophagy as potential molecular mechanisms governing the 
cardiotoxicity induced by sunitinib and ponatinib. 
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1.6.2. Hypothesis  
We hypothesize that the ribosomal S6 kinase (RSK) signaling pathway and/or 
autophagy activation mediate ponatinib and sunitinib-induced cardiotoxicity by 
inducing cardiomyocyte loss and cardiomyocyte hypertrophy. We examined the 
validity of this hypothesis by measuring the effect of RSK and autophagy inhibition 
on cardiomyocyte loss and cardiomyocyte hypertrophy (Figure 1.8). 
1.6.3. Objectives 
I. To evaluate cardiotoxic effects, manifested by H9c2 cardiomyoblast loss and 
cardiomyoblast hypertrophy, following ponatinib and sunitinib treatment. 
II. To delineate the role of RSK and autophagy as potential molecular 
mechanisms mediating ponatinib and sunitinib-induced cardiotoxicity: 
a. Validate the role of RSK and autophagy inhibition in sunitinib-induced 
H9c2 cardiomyoblast loss and cardiomyoblast hypertrophy. 
b. Explore the role of RSK and autophagy inhibition in ponatinib-induced 
H9c2 cardiomyoblast loss and cardiomyoblast hypertrophy. 
 
 
 
  
32 
 
 
Figure 1.8. Hypothetical model of sunitinib and ponatinib-induced cardiotoxicity. 
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CHAPTER 2: MATERIALS AND METHODS  
2.1. Materials  
All routine chemicals and consumables were purchased from Fisher Scientific 
(Ottawa, ON), Gibco Life Technologies (Grand Island, NY), Sigma (St. Louis, MO), 
or BD Biosciences (San Jose, CA). Tyrosine kinase inhibitors, sunitinib, free base (S-
8877), dasatinib, free base (D-3307), imatinib, free base (I-5577), and ponatinib, free 
base (P-7022), were purchased from LC Laboratories (Woburn, MA). The p90 
ribosomal S6 kinas (p90RSK) inhibitor, BI-D1870 (BID), was purchased from the 
university of Dundee (Dundee, Scotland). The autophagy inhibitor, chloroquine 
diphosphate salt (CQ) (Sigma, C-6628), was a generous gift from Dr. Shahab Uddin 
from the Hamad Medical Corporation (Doha, Qatar). Primary antibodies used for 
immunoblotting including rabbit polyclonal p-p90RSK (9341S), LC3 A/B (CS-4108) 
and rabbit monoclonal caspase-3 were from Cell Signaling Technology (Danvers, 
MA). Goat polyclonal RSK-2 (sc-1430) and rabbit polyclonal cleaved caspase-3 was 
from Santa Cruz Biotechnology (Santa Cruz, CA). Primary rabbit polyclonal α-
tubulin (Ab4074) and secondary goat polyclonal anti-rabbit IgG (Ab97051) were 
from Abcam (Cambridge, MA). Secondary donkey polyclonal anti-goat (705-035-
003) was purchased from Jackson ImmunoResearch Laboratories (West Grove, PA) 
(Table 2.1). 
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Table 2.1.  
List of the antibodies used to determine the protein expression.  
Antibody 
against 
Type Company and 
Catalog Number 
Observed 
Band Size 
Phospho-
p90RSK (P-
p90RSK) 
(S380) 
Primary Antibody; 
Rabbit polyclonal to 
Phosphorylated p90 
ribosomal protein S6 
kinase (p90RSK) 
Cell Signaling 
Technology 
(Danvers, MA); 
9341S 
90 kDa 
 
RSK-2 (C-19) Primary Antibody; Goat 
polyclonal to Ribosomal 
protein S6 kinase alpha-
3 (RSK) 
Santa Cruz 
Biotechnology 
(Santa Cruz, CA); 
1430 
80 kDa 
LC3 A/B Primary Antibody; 
Rabbit polyclonal to 
microtubule associated 
light chain 3 (LC3 A/B) 
Cell Signaling 
Technology 
(Danvers, MA); 
4108 
14 kDa (LC3 
A/B II); 16 
kDa (LC3 
A/B I) 
Cleaved 
Caspase-3 
(CC3) 
Primary Antibody; 
Rabbit polyclonal to 
Caspase-3 
Santa Cruz 
Biotechnology 
(Santa Cruz, CA); 
22171 
11, 17, 20 
kDa 
Caspase-3 (C3) Primary Antibody; 
Rabbit monoclonal to 
Caspase-3 
Cell Signaling 
Technology 
(Danvers, MA); 
14220 
17, 19, 35 
kDa 
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Antibody 
against 
Type Company and 
Catalog Number 
Observed 
Band Size 
α-tubulin Primary Antibody; 
Rabbit polyclonal to α-
tubulin 
Abcam (Cambridge, 
MA); Ab4074 
50 kDa 
Goat anti-
rabbit 
Secondary Antibody; 
Goat polyclonal 
antibody to Rabbit IgG 
(HRP) 
Abcam (Cambridge, 
MA); Ab97051 
- 
Donkey anti-
goat 
Secondary Antibody; 
Donkey polyclonal 
antibody to Goat IgG 
(HRP) 
Jackson 
ImmunoResearch 
Laboratories (West 
Grove, PA); 705-
035-003 
- 
 
 
 
2.2. Methods 
2.2.1. Culturing and Maintaining Embryonic BDIX Rat Myoblast Cell 
Line (H9c2)  
H9c2(2-1), a subclonal of the clonal cell line that is derived from BDIX 
embryonic rat cardiac tissue (176, 177) and was cultured in Dulbecco's Modified 
Eagle's Medium Ham's F-12 1:1 (DMEM/F-12) (Lonza; Basal, Switzerland) 
supplemented with 10% fetal bovine serum (FBS), 1% penicillin/streptomycin and 
incubated at 37°C in a humidified atmosphere (5% CO2, 95% O2) (177). H9c2 is a 
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well-characterized in vitro model that has been extensively used to study the 
molecular mechanism of anticancer therapy-induced cardiotoxicity, including TKIs 
(101, 178-181). Also, it has been utilized in investigating the cardioprotective effects 
of various compounds against TKIs-induced cardiotoxicity (175, 182). This wide 
utilization is due to its reproducible differentiation, preserved electrical, biochemical 
and hormonal signaling pathways (30, 176).  
2.2.2. Drug Treatment  
Stock solution of 50mM of sunitinib, dasatinib, imatinib, and ponatinib were 
dissolved separately in Dimethyl Sulfoxide Hybri-Max (DMSO) (Sigma Life Science; 
D2660). Stock solutions were further diluted in DMSO to 5mM, 10mM and finally to 
500µM and 1000µM, respectively. The final concentration of the vehicle (DMSO) in 
the medium was 0.5%. Based on our inhouse, this concentration was not cytotoxic to 
H9c2 cardiomyoblasts  
To provide an accurate comparison between groups, control group was treated 
with the same DMSO %v/v as in sunitinib or ponatinib treatment groups. In attempts 
to reduce the final concentration of DMSO, different dissolving and dilution methods 
were tried. The trials were done for the highest concentration of sunitinib (1st dilution: 
10mM and 2nd dilution: 1000µM) (Table 2.2) and trial 5 was selected.  
Ponatinib and sunitinib were used at a concentration of 2.5µM and 5µM to 
treat H9c2 cardiomyoblasts. Although the reported maximum plasma concentration 
(Cmax) of ponatinib, following a daily dose of 45mg/day, is 0.145 µM and 0.12µM 
following 44mg/day dose of sunitinib (183, 184), the concentrations used in this study 
were in agreement with previous studies (74, 101, 178, 185, 186). A previous study 
examined ponatinib-induced cardiotoxicity in hiPSC-CM. The study revealed that 48-
hours treatment with 5µM and 10µM ponatinib causes significant cell death. Authors 
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found that ponatinib caused 50% reduction in cell viability (IC50) at a concentration of 
6µM (74). Similarly, a study showed that 12-hours treatment with 2.5µM and 5µM 
sunitinib caused significant cardiac hypertrophy and increased H9c2 cell size (178).  
Two pharmacological inhibitors, BI-D1870 (BID) and Chloroquine 
diphosphate (CQ) (Sigma, C-6628) were used to investigate the molecular mechanism 
of cardiotoxicity induced by sunitinib and ponatinib. BID and CQ were dissolved and 
diluted to make 2mM stock solutions. A final concentration of 10µM BID and 10µM 
CQ was used in the current research, which is in line with previous literature (105, 
175, 187, 188). A previous study assessed the effect of different concentrations of 
BID on 54 protein kinases and showed that 10µM BID remarkably inhibited RSK1-4 
isoforms (188). In another study, CQ, at a concentration of 10µM, was used to 
evaluate the autophagic flux following sunitinib treatment in H9c2 cardiomyoblasts 
(175). 
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Table 2.2.  
Tyrosine kinase inhibitor dilution trials  
Trial Dissolved Precipitated 
1- 1st and 2nd dilutions prepared in 
1:1 DMSO:Water 
1000µM solution 10mM solution 
2- 1st dilution prepared in DMSO 
and 2nd dilution prepared in 1:1 
DMSO:Water 
10mM, 1000µM  None 
3- 1st and 2nd dilutions prepared in 
2:1 DMSO:Water 
None 10mM, 1000µM 
4- 1st dilution prepared in DMSO 
and 2nd dilution prepared in 2:1 
DMSO:Water 
10mM, 1000µM  None 
5- 1st and 2nd dilutions prepared in 
DMSO 
10mM, 1000µM None 
6- 1st dilution prepared in DMSO 
and 2nd dilution prepared in water 
10mM solution 1000µM solution 
 
 
2.2.3. Treatment Flow (Experimental flow and methods can be found in 
figures 2.1 and 2.2) 
Upon reaching confluency, cells were plated at an average seeding density of 
3 × 105 cells in 35mm culture dishes. After 24 hours, serum free media was added and 
cells were treated as following:  
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1. Screening phase: cells were treated with sunitinib (2.5μM), sunitinib (5μM), 
dasatinib (2.5μM), dasatinib (5μM), imatinib (2.5μM), imatinib (5μM), ponatinib 
(2.5μM), and ponatinib (5μM) for 24 hours. Dimethyl sulfoxide (DMSO) was 
used as a control vehicle at a final concentration of 0.5%. DMSO concentration 
used did not show a significant difference in comparison with non-treated H9c2 
cardiomyoblast cell viability (refer to section 3.1.1). In-house screening phase 
studies showed that sunitinib or ponatinib are the most cardiotoxic agents among 
the screened TKIs.   
2. Determining sunitinib and ponatinib-induced cardiotoxicity at an early time point: 
cells were treated with sunitinib (2.5μM and 5μM) and ponatinib (2.5μM and 5μM) 
for 6 hours. Dimethyl sulfoxide (DMSO) was used as a control vehicle at a final 
concentration of 0.5%. 
3. Investigating the role of p90RSK and autophagy in sunitinib and ponatinib-
induced 
cardiotoxicity using pharmacological inhibitors: H9c2 cardiomyoblasts were 
pretreated for 30 minutes with BI-D1870 (10µM) or chloroquine (10µM), then treated 
with sunitinib (2.5μM and 5μM) and ponatinib (2.5μM and 5μM) treatment for an 
additional 6 hours.  
  
40 
 
 
Figure 2.1. Experimental procedures used to determine tyrosine kinase inhibitors 
(TKIs)-induced cardiotoxicity. Step 1. Involves validating TKIs-induced 
cardiotoxicity by A) MTT B) flow cytometer analyses of cell viability, apoptosis, 
necrosis, and cell size, and C) cell surface area measurement. Step2. Involves an 
examination of molecular mechanisms of cardiotoxicity through A) quantifying 
protein expression of caspase-3, p90RSK, and LC3 by immunoblotting and B) 
quantifying gene expression of ANP by DNA gel electrophoresis. MTT, 3- (4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; p90RSK, p90 Ribosomal S6 
kinase; LC3, Microtubule-associated protein 1 light chain 3; ANP, atrial natriuretic 
peptide; DNA, Deoxyribonucleic acid. 
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Figure 2.2. A summary of the experimental flow of TKIs treatment and parameters 
analyzed.  
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2.2.4. Cell Viability Assay (MTT Assay)  
To study the cardiotoxicity of TKIs used to treat CML, we used a 1st 
generation TKI: imatinib, 2nd generation TKIs: dasatinib, sunitinib and a 3rd 
generation TKI: ponatinib on H9c2 rat cardiomyocytes. H9c2 cell viability was 
determined by 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) 
assay (Sigma, cc1001830838). MTT assay is a widely used cytotoxic assay. It 
depends on mitochondrial dehydrogenase enzymes in viable cells to reduce MTT to 
violet colored formazan precipitate with absorbance at 570nm (189). Briefly, H9c2 
cardiomyoblasts were seeded on 48-well plates at a seeding density of 4 x 104 
cells/well. Following 24 hours of various treatments, the media was aspirated and 
200µL of serum free media containing 0.5mg/mL of MTT solution was added to the 
plate and incubated for 3 hours at 37˚C. Following incubation, the media was 
carefully aspirated and 200µL of DMSO was added to solubilize the formazan 
crystals. The absorbance was measured at 570nm using a microplate reader (Epoch 2, 
BioTek).  
2.2.5. Cardiomyocyte Hypertrophy Marker 
In order to determine the role of TKIs on cardiomyoblast hypertrophic 
properties we used three distinctive makers: cell surface area, atrial natriuretic peptide 
(ANP) mRNA expression and cell size using flow cytometer. Hypertrophic stimuli 
increase H9c2 cardiomyoblast surface area, ANP and brain natriuretic peptide (BNP) 
mRNA expression and induce relative changes in cell size (178, 190, 191).  
2.2.5.1. Cardiomyocyte Hypertrophy Marker: Cell Surface Area 
In order to measure the cell surface area, an average of 10 x 104 per 35mm 
culture dish of H9c2 cardiomyoblasts were seeded for 24 hours. Following 24 hours, 
and upon reaching confluency, serum free media was added and cells were treated as 
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indicated in section 2.2.3. Next, the cells were washed with 1 x phosphate buffer 
saline, fixed with 4% formaldehyde and stained with 0.5% crystal violet. The cells 
were capture by AxioCam ERc5s (Carl Zeiss, Germany) using Axiovert 40 CFL 
inverted microscope. The surface area of an average of 15-30 of randomly selected 
cells were measured using the AxioVision Imaging software (Carl Zeiss Micro-
imaging, USA). 
2.2.5.2. Cardiac Hypertrophy Marker: ANP mRNA expression 
2.2.5.2.1. Reverse Transcription Polymerase Chain Reaction 
(RT-PCR)  
To measure ANP mRNA expression as another indicator of cardiac 
hypertrophy, an average of 3 x 105 of H9c2 cardiomyoblasts were plated in 35mm 
culture dishes for 24 hours. Upon confluency, serum free media was added and cells 
were treated as indicated in 2.2.3. RNA was isolated using Trizol RNA isolation 
procedure. 0.6 – 1µg of RNA was reverse transcribed, according to manufacturer’s 
instructions, into complementary DNA (cDNA) using a High capacity cDNA Reverse 
Transcription Kit (Applied Biosystems) (Table 2.3). Then, PCR reaction was 
performed, using 200ng of the resulted cDNA, using the following conditions: 3 
minutes initial denaturation step at 94°C, 45 seconds denaturation step at 94°C, 30 
seconds annealing step at 60°C and 1 minute extending step at 72°C. Then the 
reaction was terminated at 72°C for 10 minutes for final extension following 
completion of 35 cycles of denaturing, annealing and extending (Table 2.4). ANP 
cDNA was amplified using the primer sequences (Table 2.5). All data was normalized 
to β-actin. The final product of PCR was assessed by 2% electrophoresis agarose gels 
stained with ethidium bromide. The mRNA bands were imaged using FluorChem M 
FM0564 system (Protein Simple, USA). 
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Table 2.3  
Conditions of reverse transcription used to convert RNA into cDNA. RNA, 
ribonucleic acid and cDNA, complementary deoxyribonucleic acid. 
 Step 1 Step 2 Step 3 Step 4 
Temperature (˚C) 25˚C 37˚C 85˚C 4˚C 
Duration (minutes) 10 120 5 indefinite 
 
 
Table 2.4.  
Conditions of semi-quantitative Reverse Transcription-PCR (qPCR).  
 Temperature (˚C) Duration cycles 
Initial Denaturation 94˚C 3 minutes - 
Denaturation 94˚C 45 seconds 
3
5
 c
y
cl
es
 
Annealing 60˚C 30 seconds 
Extension 72˚C 1 minute 
Final Extension 72˚C 10 minutes - 
Hold 4˚C indefinite - 
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Table 2.5.  
List of primes used for semi-quantitative Reverse Transcription-PCR (qPCR).  
Gene Primer Sequence 
Rat ANP  
Forward 5’-CTG CTA GAC CAC CTG GAG GA-3’ 
Reverse 5’-AAG CTG TTG CAG CCT AGT CC-3’ 
Rat β-Actin  
Forward 5’-CGT CAT CCA TGG CGA ACT GG-3’ 
Reverse 5’-ACG CAG CTC AGT AAC AGT CC-3’ 
 
 
2.2.6. Flow Cytometer Studies 
Mitochondria has a major role in apoptotic cell death by releasing pro-
apoptotic proteins from intermembrane space into the cytoplasm (192). To determine 
the type of cell death seen in H9c2 treated with TKIs, H9c2 cardiomyoblasts were 
seeded at an average density of 3 x 105 on 35mm cell culture dishes in DMEM-F-12 
medium supplemented with 10% FBS and 1% penicillin/streptomycin and incubated 
for 24 hours. Upon confluency, cells were treated with CQ, BID, ponatinib and 
sunitinib with or without CQ and BID at previously mentioned concentrations and 
time points. Treatment vehicle was used as a control. Following treatment, cells were 
harvested, washed with PBS, centrifuged and equalized. Cells were then stained with 
annexin-v and propidium iodide (PI) dual staining (BD Biosciences) in 1x annexin 
binding buffer (ABB) for 30 minutes. Flow cytometry (BD LSRFortessa™ cell 
analyzer, BD Biosciences) was used to measure the cell viability (PInegative, Annexin-
FITCnegative), early (PInegative, Annexin-FITCpositive) and late (PIpositive, Annexin-
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FITCpositive) phase apoptosis and necrosis (PIpositive, Annexin-FITCnegative) as previously 
described (193, 194). Cell size was measured with forward light scatter using flow 
cytometer. Percentage of cells in early and late apoptosis were also expressed as total 
apoptosis.    
2.2.7. Immunoblotting  
Western blotting was used to measure P-p90RSK, RSK-2, LC3 A/B, cleaved 
caspase-3, and caspase-3 protein expression levels following treatment of H9c2 
cardiomyoblasts with the indicated treatment groups and time points. Briefly, at the 
treatment endpoint, H9c2 cardiomyoblasts were lysed using radio-
immunoprecipitation protein assay (RIPA) and centrifuged at 12,000-14,000 rpm at 
4˚C for 15 minutes, as described in (195). Then, the supernatant was collected. The 
protein concentration was calculated using the DC protein assay kit (Biorad). Equal 
amount of protein was resolved on 9% or 15% SDS-PAGE (sodium dodecyl sulfate 
polyacrylamide gel electrophoresis). Then, nitrocellulose membrane incubated with 
primary antibodies (P-p90RSK, RSK-2, LC3A/B, Cleaved Caspase-3, and Caspase-3) 
at 4°C overnight. All primary antibodies were used at a dilution of 1:1000 and 
secondary antibodies at a dilution of 1:4000. Anti-α-tubulin was used as a loading 
control. Visualization was performed using chemiluminescence reaction and imaged 
using FluorChem M FM0564 system (Protein Simple, California, USA). ImageJ 
software (National Institutes of Health, USA) was used to quantify the resulted bands. 
2.2.8. Evaluation of Autophagic Flux  
As discussed previously in section 1.5.2.1, LC3-II is known to present in 
autophagosomal membrane, and thus, is a commonly used marker for 
autophagosomes. However, increased level of autophagosomes does not solely 
correlate with increased autophagic activity; thus, it is important to monitor 
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autophagic flux (147, 148). To evaluate whether treatment with ponatinib and 
sunitinib alter the autophagic activity in H9c2 cardiomyoblast, the protein expression 
of LC3-II was measured in the presence or absence of CQ (147, 175). CQ, an anti-
malaria agent, increases the pH in the lysosomes, and thus, inhibits the last stage of 
autophagy, autophagosome-lysosome fusion, and inhibits the degradation of LC3-II 
(147, 196). Here, H9c2 cardiomyoblasts were pretreated with 10µM CQ for 30 
minutes followed by additional 6-hours treatment with ponatinib and sunitinib. LC3-II 
protein expression was assessed by immunoblotting. 
2.3. Statistical Analysis  
All values are compared to vehicle-treated group (control) and expressed as 
mean ± SEM. The statistical significance between individual groups was assessed 
using unpaired student’s t-test where P-value of less than or equal to 0.05 was 
considered as statistically significant. One-way analysis of variance (ANOVA) 
followed by Bonferroni correction were used to assess the multiple group 
comparisons. The Bonferroni correction is performed by dividing the α error level by 
the total number of comparisons. Herein, α error level = 0.05 (197).  
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CHAPTER 3: RESULTS 
3.1. Screening for Cardiotoxicity Induced by Various Tyrosine Kinase 
Inhibitors  
3.1.1. Cell Viability: MTT Assay 
In order to determine the cardiotoxicity induced by TKIs, we measured cell 
viability of H9c2 cardiomyoblasts using MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay, following 24-hours treatment with different 
concentrations of sunitinib, dasatinib, imatinib, ponatinib and DMSO (vehicle 
control). Treatment with 2.5µM or 5µM sunitinib caused a significant dose-dependent 
decrease in cell viability, by 4% and 22%, respectively as compared to control (95.68 
± 0.46 % and 78.12 ± 1.27 % of control; p < 0.01). Treatment with 5µM dasatinib 
resulted in a 23% reduction in cell viability (77.22 ± 2.37 % of control; p < 0.01). 
Treatment with ponatinib resulted in a severe reduction in cell viability as compared 
to control. Treatment with 2.5µM ponatinib reduced H9c2 cell viability by 22% 
(78.25 ± 3.8% of control; p < 0.05), while at 5µM, ponatinib resulted in 40% 
reduction in H9c2 cell viability (61.46 ± 1.49 % of control; p < 0.01). In contrast, 
imatinib was the safest to H9c2 cardiomyoblasts among screened TKIs. Treatment 
with 2.5µM imatinib resulted in a 9% increase in cell viability (109.19 ± 2.35% of 
control; p < 0.05) (Figure 3.1). In addition, we determined the effect of the vehicle 
control (DMSO) on H9c2 cardiomyoblast cell viability. In comparison with non-
treated H9c2 cardiomyoblasts, 0.5% of DMSO did not show a significant change in 
cell viability (Figure 3.2). Taken together, cell viability analyses using MTT assay 
show that treatment with ponatinib is associated with higher cell death as compared to 
control and other TKIs. 
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Figure 3.1. The effect of various tyrosine kinase inhibitors on the cell viability of 
H9c2 cardiomyoblasts. The cell viability of H9c2 cardiomyoblasts, treated for 24-
hours with sunitinib, dasatinib, imatinib or ponatinib, at concentrations of 2.5µM or 
5µM, was measured using MTT assay. Values are expressed as % of control (mean  
SEM, n= 3-4). *P-value < 0.05 vs control, **P-value < 0.01 vs. control and £P-value 
< 0.001 vs sunitinib 2.5µM. 
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Figure 3.2. The effect of dimethyl sulfoxide (DMSO) on H9c2 cell viability. The cell 
viability of non-treated and treated H9c2 cardiomyoblasts with 0.5% DMSO for 24 
hours, was measured using MTT assay. Values are expressed as % of control (mean  
SEM, n= 3).  
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3.1.2. Cell Viability: Flow Cytometer 
To further confirm the effect of TKIs on H9c2 cardiomyoblasts, we analyzed 
the cell viability following 24-hours treatment with various TKIs using flow 
cytometer. Our results revealed that sunitinib treatment (2.5µM or 5µM) led to severe 
cell death and resulted in more than 90% reduction in cell viability. Similarly, cellular 
exposure to ponatinib (2.5µM) caused a significant reduction in cell viability by 35% 
(64.80 ± 7.14 % of control; p < 0.05). Also, treatment with 5µM of ponatinib led to an 
80% reduction in cell viability (21.83 ± 12.74 % of control; p < 0.01). Treatment with 
dasatinib or imatinib (2.5µM or 5µM) for 24 hours did not induce cell death as 
compared to control (Figure 3.3). Taken together, cell viability analyses using flow 
cytometer show that treatment with sunitinib or ponatinib causes significant cell death 
as compared to control and other TKIs. While treatment with dasatinib or imatinib at 
comparable concentrations is not associated with H9c2 cell death.  
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Figure 3.3. The effect of sunitinib or ponatinib treatment on H9c2 cardiomyoblast cell 
viability. The cell viability of H9c2 cardiomyoblasts, treated for 24-hours with 
sunitinib, dasatinib, imatinib or ponatinib at concentrations of 2.5µM or 5µM, was 
measured by flow cytometer using propidium iodide (PI) staining solution. Values are 
expressed as % of control (mean  SEM, n= 3-4). *P-value < 0.05 vs control and **P-
value < 0.01 vs control. 
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3.1.3. Cell Death: Necrosis and Apoptosis 
We next determined the mechanism of cell death induced. We examined 
whether the treatment with 2.5µM or 5µM of sunitinib, dasatinib, imatinib or 
ponatinib for 24-hours, induce necrotic and/or apoptotic cell death. Although no 
significant change was observed for necrosis in all treatment groups (data not shown), 
apoptosis was the major mediator of sunitinib or ponatinib-induced cell death. 
Treatment with 2.5µM or 5µM sunitinib induced 300% increase in total apoptosis 
(392.28 ± 42.39% and 385.95 ± 49.56% of control; p < 0.05). Similarly, treatment 
with ponatinib induced apoptotic cell death by 72% and 200%, respectively, as 
compared to control (172.48 ± 17.47% and 299.59 ± 24.96% of control; p < 0.05 and 
p < 0.01). Treatment with dasatinib or imatinib (2.5µM or 5µM) did not induce 
apoptotic cell death (Figure 3.4). Overall, these results show that sunitinib or 
ponatinib induced-cell death in H9c2 cardiomyoblasts is mediated through apoptosis.  
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Figure 3.4. Sunitinib or ponatinib induce H9c2 cardiomyoblasts apoptotic cell death. 
Total apoptosis was analyzed by measuring annexin-v FITC expression and PI 
staining following 24-hours treatment with sunitinib, dasatinib, imatinib or ponatinib, 
at concentrations of 2.5µM or 5µM. Values are expressed as % of control (mean  
SEM, n= 3-4). *P-value < 0.05 vs control and **P-value < 0.01 vs control. 
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3.1.4. Cell Morphology and Cardiac Hypertrophy Markers: Cell Surface 
Area   
Next, we examined the effect of various TKIs on cell morphology and 
cardiomyocyte hypertrophic markers, including cell surface area and cell size. Our 
results showed that exposure of H9c2 cardiomyoblasts to sunitinib (5µM) for 24 
hours led to a significant increase in H9c2 cardiomyoblast cell surface area as 
compared to control (115.87 ± 5.26% vs. 100% control; P < 0.05). Whereas, 
exposure to ponatinib (2.5µM) induced significant H9c2 cardiomyoblast shrinkage 
(69.23 ± 9.86% vs. control; P < 0.05) (Figure 3.5 and Figure 3.6). 
Treatment with 2.5µM or 5µM ponatinib led to reduced cellular density and 
increased cellular detachment as compared to control. In addition, ponatinib induced 
cellular shrinkage (Figure 3.6).  
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Figure 3.5. Sunitinib-induced H9c2 cardiomyoblast hypertrophy and ponatinib-
induced H9c2 cardiomyoblast shrinkage. Measurement of cell surface area of an 
average of 15-30 H9c2 cardiomyoblasts treated with various TKIs following 24 hours 
treatment, using AxioVison software. Values are expressed as % of control (mean  
%SEM, n= 5-6). *P-value < 0.05 vs control. 
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Figure 3.6. Sunitinib-induced H9c2 cardiomyoblast hypertrophy and ponatinib-
induced cellular detachment and cardiomyoblast loss. Representative images of H9c2 
cardiomyoblasts stained with crystal violet following 24-hours treatment with various 
TKIs, at concentrations ranging from 2.5µM – 5µM (n=5-6). Images were captured 
with Carl Zeiss AxioVision imaging system at a magnification of 20x.  
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3.1.5. Cell Morphology and Cardiomyocyte Hypertrophic Markers: Cell 
Size  
To further confirm the effect of TKIs on H9c2 cardiomyocyte cell morphology 
and cell surface area, we assessed the cell size using flow cytometer. H9c2 
cardiomyoblasts were treated for 24 hours with 2.5µM or 5µM of sunitinib, dasatinib, 
imatinib and ponatinib. In agreement with our previous data, treatment with 2.5µM or 
5µM ponatinib led to a significant cellular shrinkage (37.59 ± 14.35% vs. control; P < 
0.05 and 1.26 ± 0.22% vs. control; P < 0.01). Moreover, in contrast to our previous 
data, sunitinib treatment (5µM) led to significant cell shrinkage (41.55 ± 6.27% vs. 
control; P < 0.01). No significant cell size change was observed following dasatinib or 
imatinib treatment (Figure 3.7). Overall, based on our data, we found that 
sunitinib or ponatinib are the most cardiotoxic among the screened TKIs. As a 
result, we selected sunitinib or ponatinib for further investigations to understand their 
molecule mechanisms of cardiotoxicity. 
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Figure 3.7. Sunitinib and ponatinib treatment causes H9c2 cardiomyoblast shrinkage. 
The cell size of H9c2 cardiomyoblasts, following 24-hours treatment with various 
TKIs, was measured by forward scatter using flow cytometer analyses. Values are 
expressed as % of control (mean  %SEM, n= 5-6). *P-value < 0.05 vs control, **P-
value < 0.01 vs control, and £P-value < 0.001 vs sunitinib 2.5µM. 
 
 
 
 
 
 
 
 
 
  
60 
 
3.2. Studies on Sunitinib and Ponatinib  
3.2.1. Cardiomyocyte Hypertrophic Markers – Atrial Natriuretic 
Peptide (ANP) mRNA Expression 
To Further investigate the hypertrophic effects of sunitinib and ponatinib in 
H9c2 cardiomyoblasts, we measured ANP mRNA expression. H9c2 cardiomyoblasts 
with treated with sunitinib or ponatinib (2.5µM or 5µM) for 24 hours. Our 
preliminary result suggested that ANP mRNA following 24-hours exposure to 
sunitinib (2.5µM) slightly increases when compared to control and other treatment 
groups (Figure 3.8).   
 
 
 
Figure 3.8. Sunitinib treatment for 24 hours induces atrial natriuretic peptide (ANP) 
mRNA expression in H9c2 cardiomyoblast. Representative agarose DNA gel of ANP 
mRNA expression in H9c2 cardiomyoblasts treated with sunitinib or ponatinib 
(2.5µM or 5µM) for 24 hours. RNA was isolated from H9c2 cardiomyoblasts, reverse 
transcribed and amplified against ANP and β-actin primers (n=1). 
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3.2.2. Apoptosis – Caspase-3 Activation  
Next, we determined whether sunitinib or ponatinib-induced apoptosis is 
through a caspase-dependent pathway. Treatment with 2.5µM sunitinib for 24 hours 
showed no change in caspase-3 protein expression (84.06 ± 7.60% vs. control; not 
significant). While treatment with 5µM sunitinib or ponatinib (2.5µM or 5µM) for 24 
hours showed 26%, 64% and 80% reduction in caspase-3 protein expression, 
respectively (74.04 ± 7.31% vs. control; P < 0.05, 35.96 ± 11.9% vs. control; P < 
0.01, and 21.71 ± 4.3% vs. control; P < 0.01) (Figure 3.9).  
Similarly, upon treatment with 5µM sunitinib or 2.5µM ponatinib, the cleaved 
caspase-3 protein expression was regressed by 46% and 67%, respectively (54.24 ± 
9.96% vs. control; P < 0.05, and 33.93 ± 9.29% vs. control; P < 0.01). While 
treatment with 2.5µM sunitinib or 5µM ponatinib showed no significant change in 
cleaved caspase-3 protein expression (70.76 ± 11.27% vs. control; not significant, and 
29.57 ± 20.17% vs. control; not significant). Together, these results show that 
sunitinib or ponatinib-induced apoptosis in H9c2 cardiomyoblasts is not mediated 
through a caspase-3 dependent pathway. 
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A) 
 
B) 
 
Figure 3.9. Sunitinib or ponatinib-induced apoptosis is not mediated through a 
caspase-3 pathway in H9c2 cardiomyoblasts. H9c2 cardiomyoblasts were treated with 
sunitinib or ponatinib (2.5µM or 5µM) for 24 hours and caspase-3 protein expression 
was measured by immunoblotting. A) Representative caspase-3 western blot and B) 
Quantification of caspase-3 protein expression after normalization to α-tubulin. 
Values are expressed as % of control (mean  %SEM, n=3-4). *P-value < 0.05 vs 
control and **P-value < 0.01 vs control.  
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3.3. Molecular Mechanisms of Cardiotoxicity Induced by Sunitinib and 
Ponatinib  
3.3.1. Role of p90 Ribosomal S6 Kinase (p90RSK) Activation in 
Sunitinib and Ponatinib-Induced Cardiotoxicity 
We next examined the potential molecular mechanism mediating sunitinib or 
ponatinib cardiotoxicity. H9c2 cardiomyoblasts were treated with sunitinib or 
ponatinib (2.5µM or 5µM) for 24 hours and P-p90RSK and RSK-2 protein expression 
were measured by immunoblotting. Treatment with sunitinib (2.5µM or 5µM) showed 
no change in P-p90RSK protein expression (118.5 ± 22.29% vs. 100% control; not 
significant and 168 ± 22.84% vs. 100% control; not significant). In contrast, treatment 
with 2.5µM ponatinib for 24 hours significantly increased p90RSK phosphorylation 
(606.18 ± 99.71% vs. 100% control; P < 0.01) (Figure 3.10). 
In terms of total RSK2 protein expression, treatment with sunitinib (2.5µM) 
led to 14% increase in the expression (114.25 ± 4.59% vs. 100% control; P < 0.05). In 
contrast, treatment with 2.5µM of ponatinib regressed RSK2 expression by 50% (47.3 
± 8.57% vs. 100% control; P < 0.01). 
Cellular exposure to 2.5µM sunitinib led to a significant decrease in 
p90RSK/RSK2 ratio (83.45 ± 2.06% vs. 100% control; P < 0.05), whereas, treatment 
with 2.5µM ponatinib significantly induced p90RSK/RSK2 ratio (2060.14 ± 570.3% 
vs. 100% control; P < 0.05). It is noteworthy that 24-hours treatment with high 
concentrations of ponatinib resulted in lower tubulin protein expression compared to 
control, which is indicative of a lower protein lysate concentration. Collectively, our 
results suggest that ponatinib mediates p90RSK phosphorylation which might be 
implicated in its cardiotoxicity. Further studies employing lower concentrations or 
shorter time points are necessary to maximize the protein lysate concentrations. 
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A) 
 
B) 
 
Figure 3.10. Ponatinib induces p90 Ribosomal S6 kinase (p90RSK) phosphorylation 
in H9c2 cardiomyoblasts. H9c2 cardiomyoblasts were treated with 2.5µM or 5µM of 
sunitinib or ponatinib for 24 hours. A) Representative phospho-p90RSK (P-p90RSK) 
and RSK2 western blots and B) Quantification of P-p90RSK protein expression after 
normalization to α-tubulin. Values are expressed as % of control (mean  %SEM, 
n=3-4). **P-value < 0.01 vs control.  
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3.3.2. Role of Autophagy in Sunitinib and Ponatinib-Induced 
Cardiotoxicity 
We also examined the role of autophagy in sunitinib or ponatinib-mediated 
cardiotoxicity by measuring the protein expression of LC3-I and LC3-II following 24-
hours. Treatment with 2.5µM ponatinib led to a significant increase of LC3-II:LC3-I 
ratio as compared to control (526.72 ± 101.1% vs. 100% control; P < 0.05). Treatment 
with 5µM ponatinib showed non-significant increase in LC3-II:LC3-I protein 
expression (2439.43 ± 875.97% vs. 100% control; not significant). Whereas sunitinib 
treatment (2.5µM or 5µM) showed no significant alteration in autophagy as compared 
to control (125.8 ± 13.84% vs. 100% control; not significant and 168.87 ± 44.4% vs. 
100% control; not significant) (Figure 3.11). Taken together, these results show that 
ponatinib modulate cardiac autophagy and could be a potential mechanism of 
ponatinib-mediated cardiotoxicity. Further studies are needed to confirm whether 
ponatinib induces or regresses autophagic flux. 
 
 
 
 
 
 
 
 
 
 
 
  
66 
 
A) 
 
B) 
 
Figure 3.11. Ponatinib treatment activates cellular autophagy in H9c2 
cardiomyoblasts. H9c2 cardiomyoblasts were treated with 2.5µM or 5µM of sunitinib 
or ponatinib for 24 hours. LC3 protein expression was measured by immunoblotting 
techniques. A) Representative LC3-I and LC3-II western blot and B) Quantification 
of LC3-II:LC3-I protein expression after normalization to α-tubulin. Values are 
expressed as % of control (mean  %SEM, n=3-4). *P-value < 0.05 vs control. 
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Table 3.1.  
Summary of Findings – Sunitinib or ponatinib-Induced Cardiotoxicity: 24 hours. 
Arrows denote significance compared to control (↑: increase; ↓: decrease; -: no 
change; N/A: not applicable). 
Parameter Sunitinib 
2.5µM 
Sunitinib 
5µM 
Ponatinib 
2.5µM 
Ponatinib 
5µM 
Cell Viability 
MTT ↓ ↓ ↓ ↓ 
Flow Cytometer ↓ ↓ ↓ ↓ 
Mechanism of Cell Death 
Apoptosis ↑ ↑ ↑ ↑ 
Caspase-3 - ↓ ↓ ↓ 
Necrosis - - - - 
Cardiac Hypertrophy 
Cell Area - ↑ ↓ - 
Cell Size - ↓ ↓ ↓ 
ANP (n=1) ↑ N/A N/A N/A 
p90 Ribosomal S6 Kinase Pathway  
P-p90RSK - - ↑ - 
RSK2 ↑ - ↓ - 
P-p90RSK:RSK2 ↓ - ↑ - 
Autophagy Pathway 
LC3-I - - ↓ - 
LC3-II - - - - 
LC3-II:LC3-I - - ↑ - 
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3.4. Cardiotoxic Studies of Sunitinib and Ponatinib – Reduced Treatment 
Duration 
Due to severe cardiotoxicity induced by sunitinib or ponatinib following 24 
hours treatment in H9c2 cardiomyoblasts as manifested by cardiomyoblast loss 
and low protein lysate concentration, we studied the cardiotoxic parameters 
following 6-hours treatment. 
3.4.1. Cell Viability  
To determine the effect of 6-hours treatment with sunitinib or ponatinib, we 
measured the H9c2 cardiomyoblast cell viability using flow cytometer analyses. 
Sunitinib treatment led to a significant dose-dependent reduction in H9c2 cell 
viability by 7% and 13%, respectively (93.21 ± 0.38% of control; p < 0.01 and 86.73 
± 0.69% of control; p < 0.01). Similarly, ponatinib treatment (2.5µM) induced a 7% 
reduction in cell viability (92.31 ± 0.56% of control; p < 0.01) while treatment with 
5µM resulted in a 14% cell viability reduction as comparted to control (86.04 ± 
2.02% of control; p < 0.05) (Figure 3.12). Together, our results suggest that sunitinib 
or ponatinib-induced cardiotoxicity starts at an early time-point, which is less 
detrimental as compared to 24-hours treatment.  
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Figure 3.12. Sunitinib and ponatinib treatment reduced H9c2 cardiomyoblast cell 
viability following 6-hours treatment. The cell viability of H9c2 cardiomyoblasts, 
treated for 6 hours with sunitinib or ponatinib (2.5µM or 5µM), was measured by 
flow cytometer analysis using annexin-v FITC and PI dual staining. Values are 
expressed as % of control (mean  %SEM, n= 3-4). *P-value < 0.05 vs control, **P-
value < 0.01 vs control, and ¶P-value < 0.01 vs sunitinib 2.5µM. 
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3.4.2. Cell Death: Necrosis and Apoptosis 
We examined whether exposure to sunitinib or ponatinib in H9c2 
cardiomyoblasts for 6 hours induces necrotic and/or apoptotic cell death. Similar to 
treatment of H9c2 cardiomyoblasts with sunitinib or ponatinib for 24 hours, no 
significant difference was seen between the most treatment groups and the respective 
concentrations vs. control in relation to necrosis. However, treatment with sunitinib 
(2.5µM) induced a significant reduction in necrosis (34.54 ± 13.4% of control; p < 
0.05); indicating that necrosis is not a key cell death mechanism induced by sunitinib 
or ponatinib (Figure 3.13, A).  
In terms of apoptosis, treatment with sunitinib or ponatinib (2.5µM or 5µM) 
led to a significant increase in total apoptosis following 6-hours treatment (Figure 
3.13, B). Overall, our results suggest that apoptosis is a key mechanism of H9c2 
cardiomyoblasts cell death induced by sunitinib or ponatinib following 6 hours of 
treatment. 
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A) 
 
B) 
 
Figure 3.13. Sunitinib or ponatinib treatment for 6 hours regresses necrosis and 
induces apoptosis. H9c2 cardiomyoblasts were treated with 2.5µM or 5µM. A) 
Necrosis and B) total apoptosis parameters were analyzed using annexin-v FITC and 
PI dual staining. Values are expressed as % of control (mean  %SEM, n= 3-4). *P-
value < 0.05 vs control, **P-value < 0.01 vs control, and ¶P-value < 0.01 vs sunitinib 
2.5µM. 
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3.4.3. Cell Morphology and Cardiomyocyte Hypertrophic Markers: Cell 
Size  
To verify whether 6-hours treatment with sunitinib or ponatinib alter H9c2 
cardiomyoblast morphology and hypertrophic makers, we first examined the effect on 
cell size using flow cytometer. In contrast to 24 hours, 6-hours exposure to sunitinib 
or ponatinib (2.5µM or 5µM) did not show a significant change in cell size (Figure 
3.14).  
 
 
 
Figure 3.14. Effect of 6 hours treatment with sunitinib or ponatinib on H9c2 
cardiomyoblast cell size. Forward scatter flow cytometer analyses were conducted 
following 6-hours treatment with sunitinib and ponatinib (2.5µM or 5µM) to measure 
H9c2 cell size. Values are expressed as % of control (mean  %SEM, n= 3).  
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3.4.4. Cell Morphology and Cardiomyocyte Hypertrophic Markers: 
Atrial natriuretic peptide (ANP) mRNA Expression 
We also examined the effect of 6-hours treatment with sunitinib or ponatinib 
on ANP mRNA expression in H9c2 cardiomyoblasts. Our preliminary result showed a 
high expression of ANP mRNA following ponatinib treatment (5µM). In contrast to 
our 24-hours, sunitinib did not show ANP mRNA expression, which might indicate a 
time-dependent effect of sunitinib or ponatinib (Figure 3.15).  
Together, our data suggest that 6-hours treatment with sunitinib and ponatinib 
might induce a time-dependent H9c2 cardiomyoblast hypertrophy. Further studies are 
required to confirm this notion.  
 
 
 
Figure 3.15. Ponatinib treatment for 6 hours induces atrial natriuretic peptide (ANP) 
mRNA expression. An agarose DNA gel of ANP mRNA expression in H9c2 
cardiomyoblasts treated with 2.5µM or 5µM of sunitinib or ponatinib for 6 hours. 
RNA was isolated from H9c2 cardiomyoblasts, reverse transcribed and amplified 
against ANP and β-actin primers (n=1). 
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Table 3.2.  
Summary of Findings – Sunitinib or ponatinib-Induced Cardiotoxicity: 6 hours. 
Arrows denote significance compared to control (↑: increase; ↓: decrease; -: no 
change; N/A: not applicable). 
Parameter Sunitinib 
2.5µM 
Sunitinib 
5µM 
Ponatinib 
2.5µM 
Ponatinib 
5µM 
Cell viability ↓ ↓ ↓ ↓ 
Mechanism of Cell Death    
Apoptosis ↑ ↑ ↑ ↑ 
Necrosis - ↓ - - 
Cardiac Hypertrophy    
Cell Size - - - - 
ANP - - - ↑ 
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3.5. Molecular Mechanisms of Cardiotoxicity Induced by Sunitinib and 
Ponatinib – Role of p90 Ribosomal S6 Kinase (p90RSK) and Autophagy 
Inhibition 
3.5.1. p90 Ribosomal S6 Kinase Activity 
 In order to clearly understand the role of RSK and autophagy in the sunitinib 
and ponatinib, we treated H9c2 cardiomyoblasts with sunitinib or ponatinib the in 
the presence and absence of pharmacological inhibitors of RSK and autophagy using 
BID and CQ, respectively.  
Firs, we examined the inhibitory effect of BID (RSK inhibitor) on P-p90RSK 
and RSK2 under our experimental conditions. H9c2 cardiomyoblasts were 
pretreated with 10µM BID for 30 minutes and subsequently treated with sunitinib or 
ponatinib for additional 6 hours. 
3.5.1.1. Sunitinib-Mediated Regression of p90 Ribosomal S6 Kinase  
In comparison to control, treatment with 10µM BID showed no significant 
change in P-p90RSK protein expression (144.8 ± 21.94% of control; not significant). 
Sunitinib treatment (2.5µM) led to a significant decrease of phosphorylated p90RSK 
as compared to control (87.04 ± 5.44% of control; p < 0.05), while pretreatment with 
10µM BID showed no significant change (114.6 ± 27.42% of control; not significant). 
In addition, treatment with 5µM sunitinib in the presence or absence of BID showed 
no significant change in P-p90RSK protein expression (100.65 ± 9.54% of control and 
118.58 ± 29.77% of control; not significant). Furthermore, pretreatment with 10µM 
BID followed with treatment with sunitinib (2.5µM or 5µM), showed a non-
significant trend towards an increase in P-p90RSK protein expression as compared to 
treatment with sunitinib (2.5µM or 5µM) alone. This may indicate the presence of 
synergistic effect between both compounds. 
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In terms of total RSK2, treatment with 10µM BID significantly reduced RSK2 
protein expression in comparison to control (62.16 ± 2.44% of control; p < 0.01). 
Treatment with 2.5µM sunitinib in the presence or absence of BID showed no 
significant change (95.18 ± 6.04% of control and 71.73 ± 11.26% of control; not 
significant). Similarly, treatment with 5µM sunitinib in the absence of 10µM BID 
showed no significant change in RSK2 protein expression (92.38 ± 5.97% of control; 
not significant) whereas in presence of 10µM BID caused a 33% reduction in RSK2 
protein expression as compared to control (66.90 ± 8.83% of control; p < 0.05). 
Moreover, pretreatment with 10µM BID followed with treatment with sunitinib 
(2.5µM or 5µM), showed a non-significant trend towards a decrease in RSK2 protein 
expression as compared to treatment with sunitinib (2.5µM or 5µM) alone. This may 
indicate the presence of synergistic effect between both agents. 
Furthermore, treatment with 10µM BID showed no significant change in P-
p90RSK:RSK2 protein expression (262.71 ± 54.05% of control; not significant). In 
addition, treatment with 2.5µM sunitinib led to a significant reduction in P-
p90RSK:RSK2 protein expression (83.90 ± 5.06% of control; p < 0.05), whereas no 
significant was observed in the presence of BID (144.51 ± 38.82% of control; not 
significant). Moreover, treatment with 5µM sunitinib in the presence or absence of 
10µM BID showed no significant change in P-p90RSK:RSK2 protein expression 
(100.24 ± 9.05% of control; and 140.90 ± 36.2% of control; not significant) (Figure 
3.16). Furthermore, pretreatment with 10µM BID followed with treatment with 
sunitinib (2.5µM or 5µM), showed a non-significant trend towards an increase in P-
p90RSK:RSK2 protein expression as compared to treatment with sunitinib (2.5µM or 
5µM) alone. This may indicate the presence of synergistic effect between both agents. 
Together, these results suggest that 10µM BID is able to regress RSK expression. 
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Also, our findings confirm that treatment with sunitinib at 2.5µM but not at 5µM 
inhibits p90RSK phosphorylation. 
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A) 
 
B) 
 
Figure 3.16. Sunitinib treatment for 6 hours reduces phosphorylation of p90RSK 
protein expression. H9c2 cardiomyoblasts were pretreated with 10µM BID for 30 
minutes and subsequently incubated with 2.5µM or 5µM sunitinib for 6 hours. RSK2 
phospho-p90RSK (P-p90RSK) protein expression was measured by immunoblotting. 
A) Representative P-p90RSK and RSK-2 western blots and B) Quantification of P-
p90RSK:RSK2 blot after normalization to α-tubulin. Values are expressed as % of 
control (mean  %SEM, n=3-11). *P-value < 0.05 vs control. 
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3.5.1.2. Ponatinib-Mediated Induction of p90 Ribosomal S6 Kinase  
In comparison to control, treatment with 10µM BID significantly increased the 
P-p90RSK protein expression (164.58 ± 5.08% of control; p <0.01). Similarly, 
treatment with ponatinib (2.5µM or 5µM) induced the phosphorylated form of 
p90RSK by 74% and 97%, as compared to control, respectively (174.32 ± 20.90% of 
control; p < 0.01 and 197.62 ± 20.70% of control; p < 0.01). Treatment with ponatinib 
(2.5µM or 5µM) in the presence of 10µM BID did not show a significant change in P-
p90RSK protein expression in comparison to ponatinib alone.   
In terms of total RSK2 protein expression, 10µM of BID was enough to 
significantly regress RSK2 protein expression by 40% as compared to control (64.97 
± 6.50% of control; p < 0.01). In comparison to control, treatment with 2.5µM 
ponatinib in the presence or absence of 10µM BID reduced the protein expression of 
RSK2 (86.16 ± 5.13% of control and 65.14 ± 10.18% of control; p < 0.05, 
respectively). Likewise, treatment with 5µM ponatinib in the presence or absence of 
10µM BID caused a reduction in RSK2 protein expression as compared to control 
(68.54 ± 9.05% of control and 55.8 ± 5.6% of control; p < 0.01, respectively). 
Moreover, pretreatment with 10µM BID followed with treatment with ponatinib 
(2.5µM or 5µM), showed a non-significant trend towards a decrease in RSK2 protein 
expression as compared to treatment with ponatinib (2.5µM or 5µM) alone. This 
shows a possibility of synergistic effect between ponatinib and BID. 
In terms of p90RSK:RSK2 ratio, treatment with ponatinib (2.5µM or 5µM) 
led to a significant increase of p90RSK:RSK2 protein expression (184.18 ± 24.35% 
and 265.5 ± 39.98% of control; p < 0.01). Similarly, treatment with BID alone or in 
combination with 2.5µM or 5µM ponatinib caused a significant increase of 
p90RSK:RSK2 ratio (294.87 ± 36.9% of control; p < 0.05; 221.8 ± 34.31% of control; 
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p < 0.05; and 215.07 ± 9.45% of control; p < 0.01), respectively. Furthermore, 
pretreatment with 10µM BID followed with treatment with ponatinib (2.5µM), 
showed a non-significant increase in P-p90RSK:RSK2 protein expression as 
compared to treatment with ponatinib (2.5µM) alone, which may indicate a possible 
synergistic effect between the two compounds. In contrast, pretreatment with 10µM 
BID followed with treatment with 5µM ponatinib, showed a non-significant decrease 
in P-p90RSK:RSK2 protein expression as compared to treatment with 5µM ponatinib 
alone (Figure 3.71). Collectively, our results indicate that, in contrast to sunitinib, 
ponatinib treatment induces p90RSK phosphorylation while stabilizing RSK2 
expression. 
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A) 
 
B) 
 
Figure 3.17. Ponatinib treatment for 6 hours induces phosphorylation of p90RSK 
protein expression. H9c2 cardiomyoblasts were pretreated with 10µM BID for 30 
minutes and subsequently incubated with 2.5µM or 5µM ponatinib for 6 hours. RSK2 
phospho-p90RSK (P-p90RSK) protein expression was measured by immunoblotting. 
A) Representative P-p90RSK and RSK2 western blots and B) Quantification of P-
p90RSK:RSK2 blot after normalization to α-tubulin. Values are expressed as % of 
control (mean  %SEM, n=3-10). *P-value < 0.05 vs control and **P-value < 0.01 vs 
control. 
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3.5.2. Evaluation of Autophagic flux  
Our previous findings revealed a trend towards an increase of LC3-II:LC3-I 
protein expression following 24-hours treatment with sunitinib and a significant 
increase following treatment with 2.5µM ponatinib. However, whether sunitinib 
or ponatinib alters the autophagic flux following 6-hours treatment is not known. 
Herein, we characterized the effect of sunitinib or ponatinib on autophagic activity 
using autophagosome-lysosome fusion inhibitor, CQ. To evaluate autophagic flux, 
H9c2 cardiomyoblast were pretreated with 10µM CQ for 30-minutes and then 
incubated with sunitinib or ponatinib for additional 6-hours, protein expression of 
LC3-II was then analyzed. 
Increased LC3-II protein expression following drug treatment in the presence 
of CQ suggests that the drug induces autophagic flux. Whereas unchanged LC3-II 
protein expression suggests that the drug accumulates autophagosome by blocking 
autophagic degradation. 
3.5.2.1. Sunitinib-Mediated Induction of Autophagy  
Treatment with 2.5µM or 5µM sunitinib for 6-hours led to a significant 
increase in LC3-II protein expression as compared to control (169.45 ± 19.45% of 
control; p < 0.01 and 217.93 ± 28.25% of control; p < 0.01). Treatment with 
10µM did not cause a significant  change in LC3-II as compared with control 
(146.41 ± 33.11% of control; not significant). Likewise, in comparison to control, 
treatment with sunitinib (2.5µM or 5µM) in the presence of CQ did not show a 
significant change in LC3-II protein expression. As compared to sunitinib (2.5µM 
or 5µM) alone, pretreatment with 10µM CQ, showed a non-significant trend 
towards an increase of LC3-II protein expression, which may indicate a possible 
induction of autophagic flux (Figure 3.18). Taken together, our results show that 
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sunitinib might induce autophagy.  
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A)  
 
B) 
 
Figure 3.18. The effect of 6-hours treatment sunitinib on autophagic flux. H9c2 
cardiomyoblasts were pretreated with 10µM CQ for 30 minutes and subsequently 
treated with 2.5µM or 5µM of sunitinib for 6 hours. A) Representative LC3-I and 
LC3-II western blot and B) Quantification of LC3-II blot after normalization to α-
tubulin. Values are expressed as % of control (mean  %SEM, n=3-8). *P-value < 
0.05 vs control and **P-value < 0.01 vs control. 
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3.5.2.2. Ponatinib-Mediated Induction of Autophagy  
Treatment with 2.5µM or 5µM ponatinib for 6-hours significantly increased 
LC3-II protein expression, as compared to control (228.11 ± 27.74% and 322.9 ± 
53.06% of control; p < 0.01). Similarly, treatment with 10µM CQ increased LC3-II 
protein expression as compared to control (181.44 ± 23.46% of control; p < 0.05). In 
comparison to control, treatment with ponatinib (2.5µM or 5µM) in the presence of 
CQ caused a significant increase in LC3-II protein expression (254.98 ± 48.23% of 
control and 510.9 ± 132.1% of control; p < 0.05, respectively). As compared to 
ponatinib (2.5µM or 5µM) alone, pretreatment with 10µM CQ, showed a non-
significant trend towards an increase of LC3-II protein expression, which may 
indicate a possible induction of autophagic flux (Figure 3.19). Taken together, our 
results show that ponatinib might induce autophagy. 
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A) 
 
B) 
 
Figure 3.19. The effect of 6-hours treatment ponatinib on autophagic flux. H9c2 
cardiomyoblasts were pretreated with 10µM CQ for 30 minutes and subsequently 
treated with 2.5µM or 5µM of ponatinib for 6 hours. A) Representative LC3-I and 
LC3-II western blot and B) Quantification of LC3-II blot after normalization to α-
tubulin. Values are expressed as % of control (mean  %SEM, n=4-9). *P-value < 
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0.05 vs control and **P-value < 0.01 vs control. 
3.5.3. Cell Viability  
Next, we examined the role of RSK and autophagy inhibition, by BID and CQ, 
respectively, in cardiotoxicity induced by sunitinib or ponatinib. H9c2 
cardiomyoblasts were pretreated with 10µM BID or CQ for 30 minutes and 
subsequently treated with sunitinib or ponatinib (2.5µM or 5µM) for additional 6 
hours. H9c2 cardiomyoblast cell viability was measured using PI staining solution by 
flow cytometer.  
Treatment with 10µM BID  led to a significant reduction in H9c2 
cardiomyoblast cell viability as compared to control (77.81 ± 1.6% of control; p < 
0.01). Treatment with 10µM CQ did not show a significant change in H9c2 
cardiomyoblast cell viability. In comparison to control, treatment with sunitinib or 
ponatinib (2.5µM or 5µM) significantly reduced H9c2 cardiomyoblast cell viability. 
In addition, pretreatment with 10µM BID or 10µM CQ followed with sunitinib or 
ponatinib (2.5µM or 5µM) treatment resulted in a significant reduction in H9c2 cell 
viability as compared with control. Moreover, pretreatment with 10µM BID followed 
with 2.5µM ponatinib resulted in a significant reduction in H9c2 cell viability as 
compared with ponatinib (2.5µM) treatment alone. A similar non-significant trend 
was observed with sunitinib (2.5µM or 5µM) or ponatinib (5µM) treatment in the 
presence of 10µM BID. While pretreatment with 10µM CQ followed with treatment 
with ponatinib or sunitinib (2.5µM or 5µM) showed no significant change in H9c2 
cell viability as compared to ponatinib or sunitinib (2.5µM or 5µM) alone (Figure 
3.20). Taken together, RSK inhibition exacerbates ponatinib and sunitinib-induced 
cell death.  
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Figure 3.20. Effect of RSK and autophagy inhibition on sunitinib or ponatinib on 
H9c2 cardiomyoblast cell viability. H9c2 cardiomyoblasts were pretreated with 10µM 
of BID or CQ for 30 minutes and subsequently treated with 2.5µM or 5µM of 
ponatinib for 6 hours. The cell viability was measured by flow cytometer analysis 
using annexin-v FITC and PI dual staining. Values are expressed as % of control 
(mean  %SEM, n= 4). *P-value < 0.05 vs control, **P-value < 0.01 vs control, $P-
value < 0.0001 vs cells treated with ponatinib 2.5µM. 
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3.5.4. Cell Death: Necrosis and Apoptosis  
Next, we examined the effect RSK and autophagy inhibition (using BID or 
CQ) on the mechanism of cell death induced by sunitinib or ponatinib treatment. 
H9c2 cardiomyoblasts were pretreated with BID or CQ for 30 minutes and 
subsequently treated with 2.5µM or 5µM sunitinib or ponatinib for an additional 6 
hours. Necrotic and apoptotic H9c2 cardiomyoblast death was measured by flow 
cytometer.  
Treatment with 10µM BID led to necrotic cell death as compared to control 
(180.71 ± 17.2% of control; p < 0.05). Although treatment with 2.5µM ponatinib 
caused a significant reduction in necrosis, in comparison to control (83.41 ± 3.03% of 
control; p < 0.05), pretreatment with 10µM BID significantly increased necrotic cell 
death, as compared to control (178.91 ± 23.75% of control; p < 0.05). Pretreatment 
with 10µM BID followed with treatment with ponatinib or sunitinib (2.5µM or 5µM) 
showed a non-significant increase in necrotic cell death as compared to ponatinib or 
sunitinib (2.5µM or 5µM) alone, which indicates that RSK inhibition might mediate 
necrotic cell death. 
Treatment with 10µM CQ did not induce a significant change in necrosis, as 
compared to control (83.97 ± 8.63% of control; not significant). In addition, 
pretreatment with 10µM CQ followed with treatment with ponatinib or sunitinib 
(2.5µM or 5µM) showed no significant change in necrotic cell death as compared to 
ponatinib or sunitinib (2.5µM or 5µM) alone (Figure 3.21).  
Moreover, treatment with 10µM BID significantly induced apoptotic 
cardiomyoblast cell death (241.88 ± 24.5% of control; p < 0.01). In addition, 
pretreatment with BID followed with ponatinib or sunitinib (2.5µM or 5µM) showed 
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a trend towards an increase in apoptotic cell death compared to treatment with 
ponatinib or sunitinib alone. In addition, treatment with 10µM CQ showed no change 
in apoptotic cell death as compared to control (105.30 ± 12.27% of control; not 
significant). However, pretreatment with 10µM CQ followed with treatment with 
2.5µM or 5µM ponatinib or sunitinib showed a tread towards an increase in total 
apoptosis as compared to treatment with ponatinib or sunitinib alone (Figure 3.22). 
Taken together, our results show that RSK inhibition by BID mediates both necrotic 
and apoptotic H9c2 cardiomyoblast cell death, while inhibition of autophagy by CQ 
may potentiate ponatinib and sunitinib-induced apoptotic H9c2 cell death. 
 
 
 
 
 
 
  
91 
 
 
Figure 3.21. Effect of RSK and autophagy inhibition on necrotic cell death following 
ponatinib or sunitinib. H9c2 cardiomyoblasts were pretreated with 10µM of BID or 
CQ for 30 minutes and subsequently treated with 2.5µM or 5µM of ponatinib for 6 
hours. Necrosis was measured by flow cytometer analysis using annexin-v FITC and 
PI dual staining. Values are expressed as % of control (mean  %SEM, n= 3-4). *P-
value < 0.05 vs control and **P-value < 0.01 vs control.  
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Figure 3.22. Effect of RSK and autophagy inhibition on apoptotic cell death following 
ponatinib or sunitinib. H9c2 cardiomyoblasts were pretreated with 10µM of BID or 
CQ for 30 minutes and subsequently treated with 2.5µM or 5µM of ponatinib for 6 
hours. Total apoptosis was measured by flow cytometer analysis using Annexin-v 
FITC and PI dual staining. Values are expressed as % of control (mean  %SEM, n= 
4). *P-value < 0.05 vs control and **P-value < 0.01 vs control. 
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3.5.5. Apoptosis – Caspase-3 Activation 
Next, we determined whether effect of RSK and autophagy inhibition on 
apoptotic marker, caspase-3. H9c2 cardiomyoblast were pretreated with 10µM 
BID or 10µM CQ for 30-minutes and then incubated with sunitinib or ponatinib 
for additional 6-hours. 
1.6.3.1. Sunitinib or Ponatinib-Mediated Caspase-3 Regression  
Exposure to RSK or autophagy inhibitors alone did not alter caspase-3 protein 
expression in comparison to control. Treatment with 10µM BID or CQ resulted in 
no effect in caspase-3 protein expression. Pretreatment with 10µM CQ followed 
with treatment with 5µM sunitinib reduced caspase-3 protein expression as 
compared to control (72.35 ± 6.7% of control; p < 0.05). Pretreatment with 10µM 
BID followed with treatment with 2.5µM or 5µM sunitinib showed no change in 
caspase-3 protein expression as compared to sunitinib alone (Figure 3.23).  
Similarly, pretreatment with BID or CQ followed with treatment with 2.5µM 
or 5µM showed no significant change in caspase-3 protein expression (Figure 
3.24).  
Together, these findings demonstrate that sunitinib and ponatinib-induced 
H9c2 cardiomyoblast apoptotic death is not mediated via a caspase-deponent 
pathway. Further studies investigating the involvement of caspase-independent in 
this setting is required.   
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A)  
 
B)  
 
Figure 3.23. The effect of RSK and autophagy inhibition on caspase-3 protein 
expression following sunitinib treatment. H9c2 cardiomyoblasts were pretreated with 
10µM of BID or CQ for 30 minutes and subsequently treated with 2.5µM or 5µM 
sunitinib for an additional 6 hours. A) Representative caspase-3 western blot and B) 
Quantification of caspase-3 blot after normalization to α-tubulin. Values are expressed 
as % of control (mean  %SEM, n=3-6). *P-value < 0.05 vs control. 
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A)  
 
B) 
 
Figure 3.24. The effect of RSK and autophagy inhibition on caspase-3 protein 
expression following ponatinib treatment. H9c2 cardiomyoblasts were pretreated with 
10µM of BID or CQ for 30 minutes and subsequently treated with 2.5µM or 5µM 
ponatinib for an additional 6 hours. A) Representative caspase-3 western blot and B) 
Quantification of caspase-3 blot after normalization to α-tubulin. Values are expressed 
as % of control (mean  %SEM, n=3-5). *P-value < 0.05 vs control and **P-value < 
0.01 vs control. 
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3.5.6. Cardiac Hypertrophy and Cell Morphology  
3.5.6.1. Cell Surface Area and Cell Size 
We also examined the effect of RSK and autophagy inhibition on 
ponatinib and sunitinib-induced cardiac hypertrophy and cardiomyoblast 
damage. H9c2 cardiomyoblasts cell surface area using crystal violet staining 
was measured, as an indication of cardiac hypertrophy, and cell size was 
assessed, as an indication of cellular morphology, using flow cytometer.  
Treatment with sunitinib or ponatinib (2.5µM or 5µM) in the presentence 
or absence of 10µM BID or 10µM CQ, showed no change in H9c2 cell 
surface area (Data not shown). 
Exposure to 10µM BID or 10µM CQ did not impair H9c2 cardiomyoblast 
cell size. Pretreatment with 10µM BID followed with treatment with sunitinib 
or ponatinib (2.5µM or 5µM) showed a non-significant trend towards a 
decrease in H9c2 cell size as compared to sunitinib or ponatinib treatment 
alone.  In addition, Pretreatment with 10µM CQ followed with treatment with 
sunitinib or ponatinib (2.5µM or 5µM) resulted in no effect in H9c2 cell size 
as compared to sunitinib or ponatinib treatment alone. (Figure 3.25). 
Collectively, RSK inhibition by BID might induce H9c2 cellular shrinkage. 
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Figure 3.25. The effect of RSK or autophagy inhibition on ponatinib or sunitinib-
induced cardiomyoblast damage. H9c2 cardiomyoblasts were pretreated with 10µM 
of BID or CQ for 30 minutes and subsequently treated with 2.5µM or 5µM of 
ponatinib for an additional 6 hours. H9c2 cell size was measured by forward scatter 
using flow cytometer. Values are expressed as % of control (mean  %SEM, n= 4). 
*P-value < 0.05 vs control and **P-value < 0.01 vs control. 
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CHAPTER 4: DISCUSSION 
Cardio-oncology is a multi-disciplinary field that focuses on the detection and 
treatment of cardiovascular adverse events caused by cancer therapy (7). 
Understanding the cancer pathophysiology has shifted cancer management towards a 
targeted approach. Multi-targeted TKIs, including sunitinib and ponatinib are used 
extensively in RCC and CML patients, respectively. Despite their superb anticancer 
efficacy, their use has been associated with increased risk of cardiotoxicity (30, 65, 
91, 94). Thus, it is crucial to understand the underlying molecular mechanism of 
TKIs-induced cardiotoxicity to identify novel protective measures during clinical use. 
Inhibition of RSK signaling pathway is thought to play a role in sunitinib-induced 
cardiotoxicity. Force et.al have hypothesized that sunitinib-induced RSK inhibition 
promote mitochondrial damage, cardiomyocyte apoptosis, cardiac hypertrophy and 
ventricular dysfunction (31, 35, 38). Another major factor to sunitinib-mediated 
cardiotoxicity involves the induction of cardiomyocyte autophagic activity, which 
mediates cardiomyocyte cell death (101, 175). A recent study has revealed that 
ponatinib treatment stimulates p90RSK phosphorylation in human endothelial cell 
models (137). The activation of p90RSK is thought to play a role in atherosclerosis 
and vascular adverse effects through inhibition of ERK5 atheroprotective effect (137, 
198).  
While the involvement of RSK pathway and upregulation of autophagy, in 
sunitinib-mediated cardiotoxicity, are well-addressed (31, 35, 100, 101); their 
involvement in ponatinib-mediated cardiotoxicity remains unknown. In the current 
study, we hypothesize that the RSK signaling and/or autophagy upregulation promote 
ponatinib and sunitinib-induced cardiotoxicity via inducing cardiomyocyte loss and 
hypertrophy. The objectives of this study are to: 1) evaluate the cardiotoxic effects of 
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ponatinib and sunitinib in H9c2 cardiomyoblasts; 2) explore the effect of RSK and 
autophagy inhibition in ponatinib-mediated cardiotoxicity; and 3) validate the role of 
RSK and autophagy inhibition in sunitinib-mediated cardiotoxicity. 
In the present study, 4 TKIs were screened (imatinib, dasatinib, sunitinib, and 
ponatinib) for cardiotoxicity in H9c2 cardiomyoblasts. We considered two criteria for 
cardiotoxicity; cardiomyoblast loss and cardiomyoblast hypertrophy. At comparable 
treatment concentrations, we found that imatinib was the safest, to H9c2 
cardiomyoblasts, among the screened TKIs, while dasatinib caused minimal damage 
to cardiomyoblast. We found that ponatinib and sunitinib were the most toxic TKIs to 
H9c2 cardiomyoblasts and were selected for further investigations. Ponatinib and 
sunitinib were recognized as the most cardiotoxic agents, among different TKIs, in 
previous studies (73, 76, 185).  
At the initial phase, we employed ponatinib and sunitinib at concentrations of 
2.5µM and 5µM for 24 hours. However, the treatment duration was soon reduced to 6 
hours due to server myocyte loss and low protein lysate concentrations obtained 
(Figures 3.6, 3.10, and 3.11). We then examined the effect of 6-hours ponatinib and 
sunitinib treatment on H9c2 cardiomyoblast and evaluated the role of RSK and 
autophagy as a potential mechanism governing cardiotoxicity induced.  
4.1. Ponatinib and Sunitinib-Induced Cardiomyoblast Loss and Hypertrophy 
In this study, we employed H9c2 embryonic rat cardiac tissue, which is a well-
characterized in vitro model that has been used to study the molecular mechanism of 
anticancer therapy-induced cardiotoxicity, including TKIs (101, 178, 179). The 
reported Cmax of ponatinib, following a daily dose of 45mg/day, is 0.145 µM and 
0.12µM following 44mg/day dose of sunitinib (183, 184). Although the 
concentrations used in this study (2.5µM and 5µM) were higher compared to Cmax 
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levels, these concentrations are in agreement with previous studies (74, 101, 178, 185, 
186).  
Cytotoxic compounds are those that affect the cellular morphology, cellular 
growth and attachment, or reduce cellular viability (199). Cardiomyocyte loss 
mediates the pathogenesis of heart failure. In failing heart, cardiomyocyte loss occurs 
by apoptosis, necrosis, and autophagy (200, 201). Similarly, pathological cardiac 
hypertrophy, stimulated by increased pressure and neurohormonal activation, leads to 
heart failure. A hallmark feature of cardiac hypertrophy is increased expression of 
ANP, BNP, and -MHC and enlarged cardiomyocyte size (202, 203). Therefore, we 
determined the effect of ponatinib and sunitinib treatment on H9c2 cardiomyoblast 
loss and hypertrophy markers.  
4.1.1. Cardiomyoblast Loss  
Cell Viability 
Cardiomyocyte loss in failing hearts occurs due to apoptotic, necrotic, and 
autophagic cell death (200, 201). Cell viability measures the number of intact and 
viable cells in a sample (199), which also can indicate cellular loss. Our in vitro H9c2 
cardiomyoblast model, treated for 6 hours with ponatinib or sunitinib (2.5µM or 
5µM), caused a decrease in cell viability by 7% -14% (Figure 3.12). Results of the 
MTT assay, following 24 hours treatment with sunitinib or ponatinib, showed a 
maximum decline of 20% and 40% in cell viability, respectively (Figure 3.1). Various 
in vitro studies showed comparable results (74, 75, 101, 178, 185, 199). A previous 
study assessed hiPSC-CMs cell viability following 48-hours treatment with ponatinib 
using Hoechst dye. Authors found that the treatment with 5µM and 10µM ponatinib 
induced 15% and 95% reduction in cell viability, respectively (74). In comparison to 
our findings, a 48-hours treatment with 5µM ponatinib caused lesser cell death; this 
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inconsistency could be attributed to the type of cells and cell viability assay used. 
Using similar in vitro model and cell viability assay, Korashy et al. found similar 
pattern of H9c2 cell viability reduction following 24-hours treatment with 1µM, 
2.5µM, 5µM and 10µM sunitinib (178). Moreover, using the same model and 
experimental procedure, Zhao et al. found that 48-hours treatment with 4µM sunitinib 
reduced H9c2 cell viability by approximately 45% (101). This discrepancy in 
comparison to our results could be due to the duration of treatment, which could 
further reduce the cell viability. Thus, we can conclude that the experimental 
differences, including the cell type, experimental procedure, treatment duration, and 
treatment concentration could affect the cardiotoxic effects induced by sunitinib and 
ponatinib. 
To accurately determine the cell viability following ponatinib and sunitinib 
treatment we used flow cytometer assays. Our flow cytometer results showed more 
than 90% and 35% - 80% reduction in H9c2 cell viability following 24-hours 
treatment with sunitinib and ponatinib, respectively (Figure 3.3). The discrepancy 
between our MTT and flow cytometer results may be attributed, in part, to the 
experimental procedure used. Flow cytometer is an effective, accurate, and reliable 
method for single-cell analyses. However, MTT assay is a simple and inexpensive 
method that depends on an enzymatic reaction and may generate a false positive result 
(189, 199). Therefore, herein, we used MTT assay as a preliminary screening assay 
whereas we used flow cytometer cell viability assay as a secondary validation of 
results obtained. Together, these findings confirm that treatment of H9c2 cells with 
ponatinib and sunitinib treatment reduces cell viability, which may in turn be 
associated with the cardiotoxic effects. 
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Mechanism of Cell Death 
We further characterized the type of cell death induced by ponatinib and 
sunitinib. Our study showed that 6 and 24-hours treatment with ponatinib and 
sunitinib induce apoptotic cell death (Figure 3.4 and 3.13). We also demonstrated that 
apoptotic cell death at 24-hours treatment occurred via a caspase-3 independent 
pathway (Figure 3.9). These findings are in alignment with Zhao et al.’s study. They 
found that 48-hours treatment with increasing concentrations of sunitinib (1.3µM, 
2.5µM, 5µM, and 10µM) showed no change in cleaved caspase-3 and cleaved PARP 
protein expression. Using similar in vitro model, they also found that pretreatment 
with caspase inhibitor did not attenuate sunitinib-induced cell death. In this study, 
Zhao et al. demonstrated that sunitinib treatment induces autophagic cell death but not 
apoptotic cell death (101). In addition, Doherty et al. examined whether 24-hours 
treatment with 0.3µM – 10µM sunitinib was associated with caspase dependent 
apoptotic cell death, using caspase3/7 assay. They found that sunitinib-mediated 
human cardiac myocyte (HCM) cell death was through a caspase-independent 
pathway (185), which is in agreement with our results. In contrary, it was shown that 
24-hours treatment with increasing concentrations of ponatinib (50nM, 100nM, 
500nM, and 1000nM) promotes cleaved casapase-3 protein expression in NRVMs 
(76). This inconsistency in comparison to our results may be due to the cell-model 
and treatment concentration used. Collectively, our study demonstrated that sunitinib 
and ponatinib treatment induced caspase-independent apoptotic H9c2 cell death. 
Further studies using lower treatment concentrations and/or employing a caspase 
inhibitor are needed to confirm our results. In addition, there is a need to examine the 
involvement of caspase-independent effect following ponatinib and sunitinib 
treatment.  
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4.1.2. Cardiomyoblast Hypertrophy, Cell Morphology, and Cell Size 
 Our study showed that 24-hours treatment with ponatinib induces significant 
cardiomyoblast shrinkage and cellular detachment. Whereas, 24-hours treatment 
with 5µM sunitinib showed a significant increase in cardiomyoblast cell surface area 
(Figure 3.5 and 3.6). Morphologically, cellular shrinkage is indicative of apoptosis 
(203, 204), while increased cardiomyoblast cell surface area is indicative of 
cardiomyocyte hypertrophy (190). In agreement to our findings, a previous study 
found that ponatinib-treated NRVMs exhibits morphological changes, manifested by 
reduced myocyte cellular density. Hasinoff et al. found that 72-hours treatment with 
2µM ponatinib led to detachment of damaged cardiomyocyte (75). Similarly, 
treatment with sunitinib induced morphological changes in cardiac cells. It was 
shown that 48-hours treatment with 3µM sunitinib resulted in hypertrophied HCM 
cells (185). Cardiomyocyte shrinkage and hypertrophy are known characteristics of 
ponatinib and sunitinib treatment, respectively. It is therefore important to identify 
the molecular mechanisms that lead to such phenotypes. 
To further validate the effect of ponatinib and sunitinib on cardiomyocyte 
hypertrophy, we measured the expression of ANP mRNA. Our preliminary findings 
demonstrated, for the first time, that 6-hours treatment with 5µM ponatinib 
expresses ANP mRNA (Figure 3.15). In addition, 24-hours treatment with 2.5µM 
sunitinib slightly expresses ANP mRNA (Figure 3.8). Although these results were 
not replicated, previous studies showed that treatment with sunitinib results in 
cardiomyocytes hypertrophy (178, 205). Maayah et al. showed that sunitinib 
treatment induced cardiac hypertrophy in adult albino rats in vivo model and H9c2 
cardiomyoblast in vitro model. Authors found that 12-hours treatment with 5µM 
sunitinib induced ANP mRNA expression in H9c2 cardiomyoblasts. In addition, 
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their study showed similar results in rat model (205). Similarly, Korashy et al. found 
that 12-hours treatment with 2.5µM and 5µM sunitinib-induced BNP, -myosin 
heavy chain (-MHC) mRNA and protein expression in H9c2 cardiomyoblasts 
(178). Together, it is well established that sunitinib treatment induces cardiomyocyte 
hypertrophy, while it is not yet validated whether ponatinib induces cardiomyocyte 
hypertrophy. Thus, further studies are required to confirm ponatinib-induced 
cardiomyocyte hypertrophy.  
 Also, we determined H9c2 cell size using forward light scatter by flow 
cytometer. Flow cytometer is a rapid tool to assess physical changes during 
apoptotic cell death. A decrease in forward light scatter is indicative of cellular 
shrinkage, a hallmark of apoptosis (204, 206, 207). We found that 24-hours 
treatment with ponatinib (2.5µM or 5µM) and sunitinib (5µM) reduced H9c2 
cardiomyoblast cell size (Figure 3.7). Whereas no change was observed following 6-
hours treatment (Figure 3.14). Overall, our study provides an evidence that ponatinib 
and sunitinib treatment is associated with cardiotoxic side effects manifested by 
reduced in cardiomyoblast viability, cell death, morphological changes, and 
cardiomyoblast hypertrophy.  
Sunitinib Versus Ponatinib-Induced Cardiotoxicity 
Ponatinib-induced cardiotoxic effects differ from sunitinib’s. In terms of 
cardiomyoblast loss, we found that 24-hours treatment with sunitinib treatment was 
associated with higher reduction in cardiomyoblast cell viability compared with 
ponatinib. Treatment with 5µM ponatinib caused 80% reduction in H9c2 cell viability 
compared to control, while 5µM sunitinib reduced H9c2 cell viability by 97% (Figure 
3.3). Treatment with 5µM sunitinib induced 400% apoptotic cell death compared with 
control, while 5µM ponatinib treatment induced 300% apoptotic cell death (Figure 
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3.4). In terms of cardiomyoblast size and hypertrophy, we found that 24-hours 
treatment with 5µM sunitinib induced cardiomyoblast hypertrophy, while 5µM 
ponatinib treatment was associated with cellular shrinkage and cellular detachment 
(Figures 3.5, 3.6, and 3.7). At 6-hours treatment, both sunitinib and ponatinib were 
associated with comparable cardiotoxic effects (cardiomyoblast loss, hypertrophy, and 
cellular morphology). Therefore, there is a need to identify the molecular mechanisms 
that are governing ponatinib and sunitinib-induced cardiotoxic effects. 
4.2. Role of p90RSK and Autophagy in Ponatinib and Sunitinib-Induced 
Cardiomyoblast Loss and Hypertrophy 
p90RSK 
 Our study found that 24-hours treatment with ponatinib induces 
phosphorylation of p90RSK protein expression, whereas treatment with sunitinib 
reduces p90RSK phosphorylation. This finding is in agreement with previous studies 
(35, 100, 137, 138). Recently, it was shown that treatment with 150nM ponatinib 
induced p90RSK phosphorylation in human aortic endothelial cells (137). This 
agrees with a previous study which examined the biochemical inhibitory activity of 
25 kinase inhibitors on 313 protein kinases. Treatment with 1µM ponatinib resulted 
in a weak inhibition of RSK1, 2, 3, and 4 by 32%, 30%, 62%, and 13%, 
respectively. Whereas treatment with 1µM sunitinib resulted in potent inhibition of 
RSK1-4 by 95-97% (138). In addition, a kinase map interaction published by 
Karaman et al., showed that the Kd for RSK1 following treatment with 10µM 
sunitinib was 0.14µM, 0.017µM for RSK2, and 0.58µM for RSK3 (35). 
Furthermore, Hasinoff et al. showed that treatment with 0.36µM Sunitinib results in 
50% inhibition of RSK1 in NRVMs (100). Therefore, our findings indicate that 
ponatinib is an inducer of p90RSK whereas sunitinib is a potent inhibitor. Thus, it is 
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important to identify the role of p90RSK as a potential mechanism of cardiotoxicity 
induced by ponatinib or sunitinib.  
To determine the role of p90RSK in ponatinib and sunitinib-induced 
cardiotoxicity, we examined ponatinib and sunitinib-induced cardiotoxic effects 
following p90RSK inhibition by BID (will be discussed in section 4.3). Our findings 
showed that treatment with 10µM BID was enough to reduce RSK2 protein 
expression (Figure 3.16). This is in agreement with a previous study which showed 
that 10µM BID was able to completely inhibit RSK1-4 isoforms (188).  
Autophagy  
 In addition to p90RSK, we also examined the role of autophagy as another 
potential mechanism in cardiotoxicity induced by ponatinib and sunitinib. Our 
findings demonstrated that 24-hours treatment with 2.5µM ponatinib increased LC3-
II:LC3-I protein expression, whereas treatment with sunitinib did not induce a 
significant change (Figure 3.11). In agreement with our results, a previous study 
detected autophagic effect of 0.0098µM ponatinib using green fluorescent protein-
tagged LC3-B assay. Treatment with ponatinib was able to activate autophagy in 
imatinib-resistant leukemic K562 cells (208). Another study has shown that sunitinib 
treatment activates autophagy. Zhao et al. demonstrated that 48-hours treatment with 
increasing concentrations of sunitinib, (1.3µM, 2.5µM, 5µM, and 10µM), increased 
the expression of autophagy-related proteins (LC3-II and Beclin-1) in H9c2 
cardiomyoblasts. In addition, 24-hours treatment with 2.5µM sunitinib induced 
autophagy, which was manifested by visible acidic vacuoles following acridine 
orange staining (101); however, authors did not confirm whether treatment with 
sunitinib modulates the autophagic activity. Since autophagy is highly dynamic 
activity, an increase in LC3-II expression could be interpreted as both induced 
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autophagosome formation and/or dysregulated autophagosome degradation. Thus, it 
is significantly important to estimate the autophagic flux as a method of monitoring 
autophagy (146-149), which was discussed in an earlier section (1.5.2.1). Our 
findings demonstrated that treatment with ponatinib for 24 hours might modulate 
cardiac autophagy. To understand the exact effect of ponatinib and sunitinib on 
cardiac autophagy, estimating the autophagic flux is required.  
Moreover, we examined the autophagic flux, following ponatinib and sunitinib 
treatment, using an autophagy inhibitor, chloroquine (CQ). CQ acts as an autophagy 
inhibitor by blocking the final step of autophagy, i.e. autophagosome-lysosome fusion 
(209). Our study showed that 30-minute pretreatment with 10µM CQ and 6-hours 
treatment with ponatinib or sunitinib (2.5µM and 5µM) induced a trend towards an 
increase in autophagic flux (figure 3.18 and 3.19). Our results are consistent with 
Kimura et al.’s study, which found that 6-hours treatment with 15µM sunitinib in the 
presence of 10µM CQ induced autophagic flux in H9c2 cardiomyoblasts (175). In 
comparison to Kimura et al., our study did not show a significant increase in LC3-II 
protein expression. This inconsistency between the two studies could be due to high 
concentration of sunitinib used in their study, experimental conditions, and/or 
statistical measure used. In their study, authors used student-t test for multiple-group 
comparisons, which might generate false-positive results (197). In this case, ANOVA, 
followed by suitable post-hoc analysis would be considered an appropriate statistical 
measure for multiple-group comparisons (197). Overall, these findings show the 
effect of ponatinib and sunitinib treatment on cardiac autophagy.  
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4.3. Role of Inhibiting p90RSK and Autophagy in Ponatinib and Sunitinib-
Induced Cardiomyoblast Loss and Hypertrophy 
4.3.1. Cardiomyoblast Loss  
Cell Viability 
 In the current study, we found that p90RSK activity is essential for H9c2 
cardiomyoblast survival. Six-hours treatment with 2.5µM ponatinib in the presence 
of a p90RSK inhibitor (BID) caused a significant reduction in H9c2 cell viability as 
compared to treatment with 2.5µM ponatinib alone. This observation was not 
surprising as RSK regulates different cellular activities, including cell survival and 
proliferation (104-106, 108). In fact, p90RSK inhibition showed anti-tumor activity.  
It was shown that BID inhibited triple-negative breast cancer cells proliferation and 
metastatic activity (210). 
 Additionally, our study demonstrated that treatment with CQ alone did not 
reduce H9c2 cell viability, whereas a reduction was observed in combination 
treatment with sunitinib or ponatinib. This finding was supported by a previous 
study which found that CQ and sunitinib co-treatment reduces H9c2 cell viability in 
comparison to sunitinib alone (175). Furthermore, in a previous study, which 
examined whether CQ is able to modulate sunitinib-mediated cytotoxicity, authors 
found that CQ synergistically enhanced sunitinib-induced cytotoxicity in several 
tumor cell lines. In addition, they found that co-treatment with CQ further decreased 
PCNA (proliferating cell nuclear antigen, a proliferation marker) in murine tumor 
cell line as compared to sunitinib treatment alone (211). 
 In contrast, multiple studies have shown that inhibition of autophagy 
attenuates sunitinib-induced reduction in H9c2 cell viability (101, 175). Zhao et al. 
demonstrated that Beclin1 knockdown reduced sunitinib-induced H9c2 cell death 
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(101). In addition, Kimura et al. examined the protective effect of autophagy 
inhibition on sunitinib-induced cardiotoxicity. Authors showed that silencing ULK1 
(an important regulator of autophagy induction) attenuated sunitinib-mediated 
reduction in H9c2 cell viability (175). Also, they demonstrated that 3-methyladenine 
(3-MA) effectively attenuated sunitinib-induced cardiotoxicity as compared to 
bafilomycin A1 and NH4Cl (175).  
 These contradicting findings associated with CQ co-treatment may be 
dependent on autophagy phase being inhibited. Kimura et al. suggested that the 
protective effect of 3-MA was achieved by inhibiting the early phases of autophagy 
that involves PI3K (175). On the other hand, CQ inhibits the last phase of autophagy 
by inhibiting the lysosomal acidification (140). Together, these results suggest that 
RSK and autophagy inhibition, by BID and CQ, respectively, may promote 
ponatinib and sunitinib-induced cardiotoxicity via increasing cardiomyoblast death. 
Mechanism of Cell Death  
In the current study, we demonstrated the effect of p90RSK and autophagy 
inhibition in ponatinib and sunitinib-induced cardiomyoblast death. We found that 
RSK inhibition alone, by 10µM BID, or in combination with ponatinib induced 
necrotic cell death. In contrast, 10µM CQ alone or in combination with ponatinib 
and sunitinib did not activate necrotic H9c2 cell death (Figure 3.21). Our findings 
also demonstrated that p90RSK and autophagy inhibition by BID and CQ, 
respectively may potentiate ponatinib and sunitinib-induced apoptotic cell death 
(Figure 3.22). Multiple studies reported the anti-tumor effects of BID and CQ (209, 
210), which explains their toxic effects. A previous study demonstrated that CQ 
potentiates the anti-tumor efficacy of sunitinib. It was shown that combining 25µM 
CQ with 5µM and 10µM sunitinib treatment resulted in improved sunitinib-induced 
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apoptotic RCC cell death (209). Another study showed that p90RSK inhibition is 
associated with anti-tumor activity. It was shown that BID inhibited triple-negative 
breast cancer cells proliferation and metastatic activity (210). 
4.3.2. Cardiomyoblast Hypertrophy, Cell Morphology, and Cell Size 
 Our study suggested that treatment with ponatinib or sunitinib and sunitinib in 
the presence of 10µM BID may result in a decrease in H9c2 cell size, which is an 
indicative marker of cell size shrinkage and apoptosis (Figure 3.25).  
Whilst many studies have linked active p90RSK to cardiomyocyte 
hypertrophy (130, 131), our findings showed no effect of p90RSK or autophagy 
inhibition (by BID or CQ, respectively) on cardiomyocyte hypertrophy following 
ponatinib or sunitinib treatment. Therefore, further research should be undertaken to 
confirm the effect of p90RSK inhibition on hypertrophic markers. 
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CHAPTER 5: CONCLUSION 
The current research indicates that the treatment with ponatinib and sunitinib 
is associated with high cardiotoxic effects manifested by increased in cardiomyoblast 
loss, morphological changes, and cardiomyocyte hypertrophy. Ponatinib and sunitinib 
treatment possessed different time and concentration-dependent cardiotoxic effects. 
Treatment with ponatinib was associated with cardiomyocyte loss, cellular shrinkage, 
and cell detachment, whereas treatment with sunitinib was associated with 
cardiomyocyte death and hypertrophy. Our in vitro H9c2 cardiomyoblast model 
suggested that treatment with ponatinib and sunitinib may induce cardiomyocyte 
hypertrophy and modulate autophagy. This study also focused on examining p90RSK 
and autophagy alterations as potential molecular mechanisms of cardiotoxicity. 
Ponatinib treatment induced p90RSK phosphorylation and autophagy, while sunitinib 
treatment inhibited p90RSK activity and induced autophagy. Inhibition of p90RSK or 
autophagy by BID or CQ, respectively may further increase cardiomyoblast loss 
induced by sunitinib or ponatinib. Additional studies are warranted to validate the role 
p90RSK and autophagy in cardiomyoblast hypertrophy. 
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5.1. LIMTATIONS  
1. One of the limitations associated with this study was the use of BI-D1870 (BID), 
which at 10µM is able to potently inhibit RSK1-4 isoforms. Besides RSK 
inhibition, BID also inhibits other protein kinases, including GSK3, PLK1, and 
MELK (121, 188, 212). Additionally, non-selective pharmacological RSK 
inhibition will poorly define the role of individual isoforms in cardiac dysfunction 
induced by ponatinib and sunitinib. Thus, for further investigations and to confirm 
our findings, specific p90RSK isoform gene silencing could be considered.  
2. In the present research, chloroquine (CQ) was used as an autophagy inhibitor. CQ 
is an autophagosome-lysosome fusion, inhibitor, it is also known to potentiate the 
cytotoxic effects of sunitinib in cancer setting (147, 196, 209). In a previous study, 
it was shown that CQ exacerbated sunitinib-induced cardiomyocyte death as 
compared to other autophagy inhibitors (175).  
3. In addition, the present study did not confirm whether ponatinib and sunitinib 
induce autophagic flux. Optimizing treatment conditions, including TKIs and 
pharmacological inhibitor concentration, and treatment time are necessary to 
understand the role of autophagy in cardiotoxicity mediated by ponatinib and 
sunitinib. 
4. Herein, we examined the caspase-dependent apoptotic cell death pathway. To 
draw a solid conclusion, further research that examines the total apoptosis 
following ponatinib or sunitinib treatment in the presence or the absence of a pan-
caspase inhibitor (for example z-VAD-fmk) is required (213). In addition, to 
understand the mechanism of ponatinib and sunitinib-induced cell death, it is 
significantly important to investigate the role of caspase-independent pathway. 
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5.2. FUTURE DIRECTIONS 
1. An in vivo, animal model could be used to validate the cardiotoxic effects of 
ponatinib and sunitinib. 
2. In line with our results, recently, it was shown that ponatinib phosphorylates 
p90RSK in human aortic endothelial cells (137). This activation is thought to 
enhance endothelial cell apoptosis, eNOS reduction, and formation of 
atherosclerosis lesion (134). Moreover, it was demonstrated that p90RSK 
inhibition induces anti-atherosclerosis effects (136). Therefore, it would be 
interesting to investigate whether p90RSK inhibition would attenuate ponatinib-
induced vascular adverse events in endothelial setting.  
3. Using an early-stage autophagy inhibitor (such as, 3-MA) or introducing 
autophagy-related gene knockdown might provide a better insight on the role of 
autophagy in ponatinib and sunitinib-mediated cardiotoxicity. 
4. It is warranted to confirm the effect of ponatinib and sunitinib on cardiomyocyte 
hypertrophic markers (including ANP, BNP, or -MHC) in the presence or 
absence of p90RSK and autophagy inhibitors. 
5. To determine the effects of clinically relevant concentrations of sunitinib and 
ponatinib on H9c2 cells, use a wider range of concentrations starting from 50nM – 
150nM (clinically relevant concentrations) for longer treatment duration and 
compare the results with 6 hours and 24 hours data. 
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